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ABSTRACT OF THE DISSERTATION
STRUCTURE AND MECHANISM OF MYCOBACTERIAL TOPOISOMERASE I
by
Nan Cao
Florida International University, 2018
Miami, Florida
Professor Yuk-Ching Tse-Dinh, Major Professor
The enzyme DNA topoisomerase I is an essential enzyme that plays an
important role in eukaryotic and prokaryotic cellular processes such as DNA
replication, transcription, recombination and repair. Mycobacterium tuberculosis
topoisomerase I (MtTOP1) is a validated drug target for antituberculosis
treatment. Mycobacterial topoisomerase I regulates the topological constraints in
chromosomes and helps in maintaining the growth of mycobacteria.

The N-

terminal domain (NTD) of mycobacterial topoisomerase I contains conserved
catalytic domains that along with the active site Tyrosine are involved in cleaving
and rejoining a single strand of DNA. Magnesium is required in DNA cleavage
activity of type IA topoisomerases. The C-terminal domain (CTD) of
mycobacterial topoisomerase I is divided into four subdomains (D5-D8) and a
positively charged tail. Each subdomain has a GxxGPY sequence motif. The
DNA binding, relaxation, cleavage, religation, catenation and decatenation ability
of each subdomains of CTD were studied. The present study shows that each
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subdomain has its own characteristics. Subdomain D8 and D7 are responsible
for maintaining the relaxation activity of mycobacterial topoisomerase I.
Subdomain D5 is essential to maintain the DNA cleavage, religation, catenation
and decatenation activity. A new crystal structure of MtTOP1-704t (amino acids
A2-T704 containing NTD+D5 domains) was obtained. Structures with ssDNA
substrate bound to the active site (Y342) in the presence and absence of Mg2+
were also investigated. Significant enzyme conformational changes upon DNA
binding place the catalytic tyrosine in a pre-transition position for cleavage of a
specific phosphodiester linkage to form a covalent intermediate. Meanwhile, the
enzyme/DNA complex with Mg2+ bound at active site may present the posttransition state for religation in the enzyme’s multiple-state DNA relaxation
activity. The critical function of a strictly conserved glutamic acid in acid-base
catalysis of the DNA cleavage step was also demonstrated by site-directed
mutagenesis. The present work provides new functional insights into the more
stringent requirement for DNA rejoining versus cleavage by type IA
topoisomerase, and further establishes the potential for select interference of
DNA rejoining via specific inhibitors.
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INTRODUCTION
I.1 Tuberculosis
Tuberculosis (TB) is a fatal airborne disease. It is a global health problem
and kills millions of people annually. In 2016, 6.3 million new TB cases were
reported, and 1.3 million people died from TB worldwide. The World Health
Organization (WHO) estimates that 10.4 million people are currently infected by
TB. Most of the new cases are in low-income countries in Asia and African. As
TB is one of the top causes of human mortality (Fogel, 2015), much effort has
been devoted to diagnosis, prevention and treatment TB. The world health
organization’s end TB strategy plans to stop TB in 2030~2035 (WHO, 2017).
Mycobacterium tuberculosis (M. tuberculosis) is a pathogenic bacterium
and is the cause of TB (Tang et al., 2016). The genome of Mycobacterium
tuberculosis H37RV was sequenced, and pathogenic factors were characterized
(Glickman and Jr., 2001). Mycobacterium tuberculosis is mainly transmitted in
the

aerosol

droplet

and

passes

through

the

upper

respiratory

tract.

Mycobacterium tuberculosis infects lungs, but the infection also involves other
organs (Piccini et al., 2014). Mycobacterium tuberculosis has the characteristics
of both Gram-negative and Gram-positive bacteria (Fu and Fu-Liu, 2002). The
cell wall of Mycobacterium tuberculosis is distinctive and impermeable. It is
difficult to characterize between Gram-negative and Gram-positive cell wall. The
thick outer layer membrane contains mycolic acid and outermost capsule
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composed of polysaccharides (Jankute et al., 2015). The three basic structure
component of Mycobacterium tuberculosis cell wall are, long-chain mycolic acids,
highly branched arabinogalactan based polysaccharide, and cross-linked
network of peptidoglycan (Figure I.1) (Bhat et al., 2017; Jankute et al., 2015;
Smith, 2017).
Smith: Nanoparticle delivery of anti-TB chemotherapy & drug resistance
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Figure 1. Basic structure of M. tuberculosis cell wall. The cell wall of Mtb is comprised
of four layers, making treatment difficult and complex. The outer layer of mycolic acids surrounds inner layers of arabinogalactin and peptidoglycan. These surround the traditional
Figure
I. 1 Thebilayer
basicofstructure
phospholipid
the cell. of Mycobacterium tuberculosis cell wall (Smith,

2017)
duces cell membrane energy, disrupting the ond-line drugs, including injectables such as
proton motive force and affecting membrane capreomycin, kanamycin, and amikacin.
transport [14]. EMB is a bacteriostatic agent These drugs have a wide range of severe and
that inhibits the polymerization of arabinan, chronic side effects, including hearing loss,
arabinogalactan, and lipoarabinomannan, diarrhea, depression, abdominal pain and
thus preventing its biogenesis formation on nausea, neurapathy, and fatigue [18]. Treatthe cell wall [15]. Drug resistance in M. tu- ment typically lasts 24 to 27 months and is
berculosis is due to spontaneous chromoso- 25 to 50 times more expensive to treat. Exmal mutations and is worsened by the 2tensively drug-resistant TB (XDR-TB) can
absence or inefficiency of resistance-medi- be defined as resistance to INH and RMP in
ating genetic elements such as transposons vitro, any of the second-line fluoroand plasmids [16,17].
quinolones, and one or more of the secondDrug resistance in TB is a direct off- line injectable drugs. There is no consensus

When M. tuberculosis initially infects the host, the infection phase is
asymptotic, and this is called the latent phase (Lipworth et al., 2016). The innate
immune and adaptive immune system of the human body will react to the bacillus
invasion (Jacobs et al., 2016), by the development of antibodies and
macrophage phagocytosis (Delogu et al., 2013; Jacobs et al., 2016).

In the

latent phase, the innate and adaptive immune system defenses can control the
reproduction of M. tuberculosis in the lung by macrophages, neutrophils,
monocytes, dendritic cells, and T cells (Fogel, 2015; Pieters, 2008).

If the

balance of immune system regulation is disturbed, the growth of M. tuberculosis
in the host out of control, M. tuberculosis develops new ways to survive under
immune defense (Pieters, 2008). The reactivation of dormant M. Tuberculosis
causes tuberculosis (Venketaraman et al., 2015). The active tuberculosis is also
called TB disease (Pai et al., 2016). Patients with TB disease are infectious and
spread M. tuberculosis through the air. About 15% of latent tuberculosis cases
will develop into active tuberculosis during the total lifetime (Connell et al., 2011).
Another issue with TB disease is that 10% of HIV positive patients are coinfected with TB (Connell et al., 2011; Sulis et al., 2014).
I.2 The prevention and treatment of tuberculosis
Decades of global efforts are developing and discovering new prevention
and treatment method to eliminate TB transmission and activation (Figure I.2).
Bacille Calmette-Guérin (BCG) is a vaccine developed from Mycobacterium
bovis strain. It was first used in the 1920s (Kaufmann, 2013). Although the
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million incident cases of tuberculosis (TB), 1.1 million deaths
from TB among human immunodeficiency virus (HIV)-negative
people, and an additional 0.4 million deaths from HIV-associated
TB1. TB is the fifth leading infectious killer of adults worldwide2,
the third largest killer of women in their reproductive years3, and
a leading infectious cause of death among people with HIV
disease2–5. In recent years, the world has seen a rapidly emerging epidemic of drug-resistant TB, multi-drug-resistant TB, and
extensively drug-resistant TB, which is lethal and extremely
expensive and complicated to treat6.

tion in the United States10, and even shorter courses of treatment
are under study (AIDS Clinical Trials Group [ACTG] study 5279,
NCT01404312).
New and old rifamycins are being repurposed at optimized
doses. Clofazimine, an iminophenazine dye used to treat leprosy,
has attracted renewed interest owing to its ability to target TB.
Fluoroquinolones have been studied for shorter treatment
durations of drug-susceptible disease, though phase III trial results
have been disappointing thus far11. Discussed in more detail below,
there are novel drugs in new classes approved and/or in clinical
trials, including bedaquiline, delamanid, pretomanid, AZD5847,
and sutezolid. Used either separately or in novel combinations,
these agents are anticipated to shorten and otherwise improve the
treatment of drug-resistant and, possibly, drug-susceptible TB.

mechanism of BCG is not well identified, it is the only licensed vaccine to against
The current first-line four-drug regimen for drug-susceptible TB

TB (Kaufmann,
could prevent TB efficiently when
is nearly 50 years old,2013).
takes six to Bacille
nine months Calmette-Guérin
to complete, and
has significant side effects. Treatment for drug-resistant TB may
take up to 30 months7. Even though more than 250,000 children
develop TB each year, inexcusably, most anti-TB agents are not
available in suitable pediatric formulations8. While liquid formulations may be easy to administer to young children, they are
bulky and more expensive, and some have unacceptable toxicity.
Only recently have TB drug dosing recommendations been revised
to reflect differences in the way children metabolize drugs and,
until recently, most first-line drugs were under-dosed9. Equally
important, the last 50 years have only brought about the FDA
licensing of two new drugs for TB treatment (rifapentine and
bedaquiline) (Figure 1). There is an urgent need for more effective
and tolerable treatment of drug-susceptible and drug-resistant
disease and latent TB infection as well as dosing strategies for
children. Regimens that can be safely co-administered with
antiretroviral therapy are also needed for the growing number of
patients co-infected with HIV and TB.

it is given in infancy or childhood (Sridevi et al., 2015; Venturini et al., 2014). The
As important as the emerging new strategies for anti-TB regimen development are regulatory changes to expedite these efforts.
Since the 1950s, TB clinical trials have consisted of addition to, or
substitution of, an existing drug in a standard regimen. Traditional
trial designs use TB cure without relapse as an endpoint, which
requires observation for the duration of treatment and then 12–18
months of follow-up. Therefore, large phase III trials often take
five or six years to complete and, with multiple compounds now in
the pipeline, the development of a novel regimen using this model
would require decades. The recent increase in global philanthropy
directed at TB and the collaborations amongst major stakeholders
have created opportunities to overcome bottlenecks and dramatically shorten the time to regimen development. For example, the
Global Alliance for TB Drug Development, which is a not-for-profit
product development partnership (PDP), is positioned to leverage a
global network of public and private partners to advance TB drug
development by developing drug combinations instead of individual drugs12. Treatment shortening remains an important goal for

meta-analysis study shows the protection ability declines after 10 year (Abubakar
et al., 2013; Alsdurf et al., 2016). Thus the TB disease occurs in adults and
adolescents (Tang et al., 2016). Studies reported new TB vaccines, and some
TB vaccine candidates are already in clinical tests, such as recombinant BCG
and There
vaccine
isolated from M. tuberculosis (Chawla et al., 2014; Pai et al., 2016).
are some positive developments, though: after a long
drought, new drugs are available, and new strategies for the
treatment of latent disease and for regimen development in active

Figure 1. Timeline for tuberculosis (TB) drug development. Major milestones in TB drug development over the last century are outlined

by the date of approval of the drug or intervention. Approval dates for drugs in development are estimated. Abbreviations: BCG, Bacillus
Figure
I.2 Drugs and vaccine development history of TB treatment (Podany and
Calmette-Guérin.
Swindells, 2016)
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The TB treatment drugs include first-line TB agents and second-line TB
agents.

The first line antituberculosis reagents include isoniazid, rifampicin,

pyrazinamide, and ethambutol (Wilby et al., 2014).
antituberculosis

reagents

include

Amikacin

The second line

capreomycin,

ciprofloxacin,

cycloserine, ethionamide, kanamycin, ofloxacin, P-aminosalicylic acid and other
drugs (Nath and Ryoo, 2013). The cell wall of M. tuberculosis is impermeable to

4

noxious compounds and drugs. Many drugs target M. tuberculosis cell walls,
such as isoniazid, ethambutol, ethionamide and other drugs (Smith, 2017).
Fluoroquinolones are being considered as new first-line agents (Takiff and
Guerrero, 2011).

Fluoroquinolones inhibit the function of DNA gyrase in M.

tuberculosis. Other drugs inhibit fatty acid biosynthesis, protein biosynthesis,
DNA based process and other metabolic processes (Janin, 2007).
The challenge of the treatment of TB is drug-resistant tuberculosis. Under
the pressure of drug treatment, M. tuberculosis develops mutations to escape
death. Drug treatment always fails in these situations.

Drug-resistant

tuberculosis includes multidrug-resistant tuberculosis (MDR-TB) and extensively
drug-resistant tuberculosis (XDR-TB).

Multidrug-resistant tuberculosis is

identified as being resistant to at least two first-line agents, especially isoniazid
and rifampicin (Mishra et al., 2015). Extensively drug-resistant tuberculosis is
identified as MDR-TB plus resistance to at least one fluoquinolone, and at least
one of the three injectable second-line agents (amikacin, capreomycin, or
kanamycin) (Jassal and Bishai, 2009). The mechanisms for drug resistance are
complex. Mycobactrium tuberculosis develops mutations that lead to drug
resistance during drug treatment. In isoniazid-resistant M. tuberculosis, mutations
of gene katG, ahpC, and inhA have been identified (Nath and Ryoo, 2013; Wilby
et al., 2014). The katG gene is essential for M. tuberculosis. It is required for
converting isoniazid to its active form (Ameeruddin and Luke Elizabeth, 2014).
Activated isoniazid targets at cell wall and inhibits the synthesis of mycolic acids,
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which is essential for the cell wall of M. tuberculosis. Other challenges to TB
treatment include first-line antituberculosis agents being given to patients for 18
DNA structure and function

A. Travers and G. Muskhelishvili

weeks (Pai et al., 2016).

The first-line drugs are efficient for overcoming

sequence information than the minor groove. HowAlthough the formation of a B-type structure is a
ever, importantly, the wide and shallow morphology
crucial aspect of DNA functionality the factors which
tuberculosis, but MDR-TB and longtime treatments are challenges to treat
of the DNA major groove is in stark contrast to the
shift the A M B equilibrium are, apart from water
narrow and deep structure of the RNA major groove.
activity, poorly understood. One aspect is base-type.
This pattern is reversed
the minor
groove.
For a for
In principle,
the coding capacity
of DNA
be
tuberculosis.
Thereforare
urgent
needs
new therapeutic
drugs
to can
shorten
the
protein DNA-binding motif, particularly one containachieved not only by the canonical A–T and G–C base
ing an a-helix, access to the DNA major groove is
pairs, but also by other possibilities. For example, a
treatment
period
and
killgroove.
M. tuberculosis
withpolymer
drug-resistant
mutations.
more facile
than to the
minor
This fundamenDNA
with diaminopurine–thymine
(DAP–T)
tal difference between DNA and RNA follows directly
and hypoxanthine–cytosine (H–C) base pairs with,
from their chemical structures. Whereas DNA can
respectively, three and two interbase hydrogen bonds
adopt (at least) two forms of right-handed double-heli(Fig. 3) would, in principle, present a similar potential
I.3 DNA
topology
cal structures,
A-DNA and B-DNA (Fig. 2A), RNA
for protein recognition and thermal stability [15].
can only form an A-type double helix because of the
Other variations would be DNA molecules in which
steric restrictions imposed by the 20 hydroxyl residue
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molecules
exist that
in proposed
differentbonds
forms
(Dai not
and
on ribose
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Changing base-pairing interactions by effectively transhydrogen
bonding.
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helix model in 1953. The DNA
double helix model was found in
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physiological conditions by X-ray crystallography by Franklin. Complementary
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pairing
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featured

B

in
this
(a)

model

(Adenine-Thymine,

Guanine-

cytosine)(Figure I.3).

(b)

Fig. 2. (A) Structures of A-DNA and B-DNA. Note the difference in groove width and the relative displacements of the base pairs from the
central axis. Reproduced with permission from Arnott [12]. (B) A–T and G–C base pairs shown for Watson–Crick pairing (a) and Hoogsteen
pairing (b). syn and anti indicated different sugar conformations. Reproduced with permission from Johnson et al. [124].

Figure I.3 Structure of B-DNA and base pairing. (Travers and Muskhelishvili, 2015)
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In eukaryotic and prokaryotic organisms, genomic DNA carries coded
information. It is crucial for the cellular process to maintain DNA topological
structure. The topological structures of DNA molecules change during cellular
processes (Vologodskii, 2010). The genomic DNA structures are dynamic and
flexible. Some of them link to each other and form different topology states, such
as DNA knots, and DNA catenates (Figure I.4) (Higgins and Vologodskii, 2015).

Figure I.4 The simple knots and catenanes. (A) Knots. (B) Catenanes. (Higgins and
Vologodskii, 2015)

Another DNA topology state is DNA supercoiling.

It is vital for DNA

replication, transcription, recombination and repair processes (Magnan and
Bates, 2015). Double-stranded DNA crosses the helical axis with two different
hand directions. Supercoiling in DNA includes negatively supercoiled DNA and
positively supercoiled DNA. Negatively supercoiled DNA is undertwisted and
responsible for DNA separation (Finzi and Dunlap, 2016). Positively supercoiled

7

is in the overtwisted state (Travers and Muskhelishvili, 2015). The topological
structures of dsDNA change during DNA replication and recombination
processes (Figure I.5).

Positively supercoiled DNA is generated during the

L. Baranello
et al. / Biochimica
Biophysica
Acta 1819Other
(2012) 632–638
transcription process
(Baranello
et etal.,
2012).
components such as DNA

633

polymerases, RNA polymerase, and DNA topoisomerases are required in DNA
transactions to maintain DNA topological structure (Koster et al., 2010; Seol and
Neuman, 2016).

Fig. 1. Basics of DNA topology and its relevance to DNA transactions. The DNA topology is described quantitatively by the twist of double helix and by the number of times the helix
crosses over on itself (plectoneme). Plectonemic structures are typically formed by bacterial plasmids. B) A graphical illustration showing the generation of supercoiling during
transcription and replication. If polymerases are moving without rotation, then due to its helical structure, the DNA must be screwed through the protein complexes. In this
case, the templates rotate around its axis as indicated by curved arrows.

Figure I.5 The generation of supercoiling during transcription and replication.
(Baranello et al., 2012)

(Fig. 1B). This hypothesis applies with minor modiﬁcation to the
movement of transcription and replication complexes as well as for
some helicase and restrictase activities [17–20]. Currently, the best
investigated example is transcription-generated supercoiling. Due to
the overwhelming molecular mass of the RNA polymerase and
given the arguments in favor of immobilization of RNA polymerase
in transcription factories, the DNA template is forced to rotate around
its axis as the double helix threaded through the transcriptional machinery [21–24]. The upstream DNA becomes untwisted, while the
downstream DNA becomes overtwisted which is referred to as negatively and positively supercoiled, respectively. If the translocation
proceeds without pauses then the RNA polymerase could generate
up to 10 supercoils per second and up to 3000 supercoils for a typical
30 kbp gene [25,26]. This enormous torsional stress might be inhibitory for efﬁcient transcription [17,27,28]. Consequently, it is relieved
by DNA topoisomerases which transiently break and rejoin the backbone of DNA [19].
Another source of DNA supercoiling is provided by the reorganization of eukaryotic chromatin: the disassembly or assembly of nucleosomes releases or absorbs DNA superhelicity. Special protein
complexes called chromatin remodelers are able to remove or slide
nucleosomes in an ATP-dependent fashion [29,30]. Notably, in vitro
experiments have shown that these chromatin remodeling activities
directly generate torsional stress of DNA in the presence of nucleosomes [31]. While the remodeling of the chromatin structure is a
broad phenomenon that could involve sometimes entire loci, it is

DNA molecule experiments in vitro have demonstrated a dynamic coupling between twisting-untwisting of the double helix and stretching
forces, a possibility which remains largely unexplored in vivo [36].
3. Tuning of transcription-generated DNA supercoiling
The level of supercoiling depends on two opposite processes: how
fast torsional stress is introduced into the DNA, and how fast it is relaxed or diffused into remote regions of the genome. The supercoil
generation in the DNA ﬂanking RNA polymerase complexes depends
on the rate of transcriptional elongation which may be relatively invariant in the absence of speciﬁc RNA polymerase pausing or stalling
and on the rate of transcriptional initiation [17,37,38]. Thus low level
transcription produces a pulse of torsional stress followed by DNA relaxation, while high level transcription, due to repetitive initiation,
may establish stable dynamic supercoiling upstream of transcription
start sites [39,40]. In the transcribed unit of highly active genes the
DNA regions between RNA polymerases transcribing in tandem contain supercoils of opposite polarity that could annihilate each other.
Other important parameters include the distribution of promoters
8
which,
in divergent orientation, could reinforce DNA supercoiling upstream transcription start sites by untwisting the double helix as well
as by inducing directly plectonemes [41], and the presence or absence
of barriers to diffusion of torsional stress [42]. The dynamics of supercoil diffusion should depend on the behavior of chromatin ﬁbers: in
principle, the position of individual nucleosomes, the interactions be-

I.4 DNA topoisomerases
I.4.1 Classification of DNA topoisomerases
James Wang discovered DNA topoisomerase in thr 1970s. It is called ω
protein and was isolated from E. coli (Depew et al., 1978).

The DNA

topoisomerases are essential enzymes that are involved in DNA replication,
recombination, transcriptional and repair processes.
topology during these processes.

They regulate DNA

These enzymes are ubiquitous in both

eukaryotes and prokaryotes. On the basis of the properties and mechanisms of
DNA topoisomerases (Table I.1), they are divided into two types: type I
topoisomerase and type II topoisomerases.
topoisomerases is a monomer.

The structure of type I

They regulate DNA topology by a single-

stranded DNA passage mechanism. The DNA type I topoisomerases cleave and
rejoin a single strand of DNA (Corbett and Berger, 2004). Type II topoisomerase
modify DNA topology by a double-stranded DNA passage mechanism, which is
ATP-dependent. There are three sub-types of type I topoisomerases, type IA
topoisomerase, type IB topoisomerase and type IC topoisomerase.

Type II

topoisomerases include type IIA topoisomerase and type IIB topoisomerases
(Table I.2).
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Activities
Relaxation
ATP
Mg(II)
Catenation/ Knotting/
dependent dependent decatenation unknotting −veb +veb

Supercoiling
−ve
+ve
Topoisomerase

Type

Enzyme
structure

No. of DNA 5′ or 3′
strands
bond
Proposed
cleaved
formed mechanism
Topo I

IA

Monomer

1

5′

Strand passage

No

Yes

Yesc

Yesc

Yes

No

No

No
Eukaryotic IB

Monomer

1

3′

Controlled
rotation

No

No

Yes

Yesc

Yes

Yes

No

No

Bacterial

IIA

Homo-dimer

2

5′

Strand passage

Yes

Yes

Yes

Yes

Yes

Yes

No

No
Topo III

IA

Monomer

1

5′

Strand passage

No

Yes

Yes

Yes

Yes

No

No

No
Topo IV

IIA

Hetero-tetramer

2

5′

Strand passage

Yes

Yes

Yes

Yes

Yes

Yes

No

No
Topo V

IB/ICa

Monomer

1

3′

Controlled
rotation

No

No

Unknown

Unknown

Yes

Yes

No

No
Topo VI

IIB

Hetero-tetramer

2

5′

Strand passage

Yes

Yes

Yes

Unknown

Yes

Yes

No

No
DNA gyrase

IIA

Hetero-tetramer

2

5′

Strand passage

Yes

Yes

Yesd

Yes

Yes

Yes

Yes

No
Reverse gyrase

a

IA

Monomer

1

5′

Strand passage

Yes

Yes

No

No

Yes

No

No

Yes
b

Topo V was originally described as type IB but has been proposed to form a new class (IC).
-ve indicates negatively supercoiled DNA; +ve indicates positively supercoiled DNA.
c
Possible only if one substrate is nicked or single stranded.
d
Decatenation by E. coli DNA gyrase is weak.
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Mutations in Salmonella enterica serovar Typhimurium
(Salmonella Typhimurium) and E. coli topo I enzymes
(topA mutations) are generally nonlethal but lead to
the acquisition of compensatory mutations in the DNA
gyrase genes, gyrA and gyrB (25, 26, 27, 28); however,
topA mutations have been shown to lead to cold sensitivity (28). Despite the apparently nonessential nature of topo I, the stabilization of the complex of topo I
and cleaved DNA induces the SOS response, leading to cell death (29). There is, therefore, potential
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An N-terminal 67-kDa fragment of E. coli topo I was the
first type I topoisomerase structure to be solved (22). The
structure forms a “base” and a “lid” around a cavity with
a diameter of 28 Å, which could accommodate doublestranded DNA. The active-site tyrosine is positioned at
the entrance to this cavity. Since then, other structures
of type I topoisomerases have been solved, including
the structure of the catalytic domain of E. coli topo I in
a covalent complex with bound DNA (Fig. 7) (23). Such
information is very valuable in terms of the design of new
antibiotics (see below).

(21). Bacterial topo I enzymes (e.g., Escherichia coli
topo I) are type IA enzymes (Table 1) and can relax
only negatively supercoiled DNA. Eukaryotic topo I
enzymes are type IB enzymes (Table 1) and can relax
both positively and negatively supercoiled DNA; they
are evolutionarily and mechanistically distinct from
the bacterial enzymes. E. coli topo I is a 97-kDa protein consisting of three domains (22). The first (Nterminal) domain, which consists of 582 amino acids
in E. coli, is responsible for cleavage and strand passage
and contains the active-site tyrosine at position 319.
The next 162 amino acids make up a Zn(II)-binding
domain that contains three tetracysteine motifs. The
C-terminal third domain, which contains 121 amino
acids, is rich in basic amino acids and contributes to
substrate binding.

Table I.1 Basic structure, mechanism and properties of different DNA topoisomerases (Bush et al., 2015)
In the proposed “enzyme-bridging” model of DNA relaxation by topo I, the enzyme cleaves a single strand
of DNA and bridges the gap through which the intact
strand is passed (22). The clamp then closes around
the intact strand, and the cleaved strand is religated. The
protein then reopens to release the passed strand and
closes again to complete the cycle (Fig. 8). Recent work
suggests that the intact strand may bind in the clamp
prior to cleavage and then pass through the enzymestabilized single-strand break (24).
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Table 1 Key properties of different topoisomerases

Type IA
topoisomerases

Bacterial and archael DNA topoisomerase I
and III
Yeast DNA topoisomerase III
Mammalian DNA topoisomerase IIIα and IIIβ

Type IB topoisomerases Eukaryotic DNA topoisomerase I
Mammalian mitochondrial DNA
topoisomerase I
Pox virus topoisomerase
Type IC
topoisomerases
Type IIA
topoisomerases

Methanopyrus topoisomerase V (Archael)
Bacterial gyrase and DNA topoisomerase IV
Yeast DNA topoisomerase II
Mammalian DNA topoisomerase IIα and IIβ

Type IIB
topoisomerases

Sulfolobus shibatae topoisomerase VI

Table I.2 Subfamilies of DNA topoisomerases (Wang, 2002)

The DNA topoisomerases cleave single or double-stranded DNA. The
active site tyrosine of DNA topoisomerases attack the phosphate in the DNA
backbone, an enzyme-DNA intermediate complex forms at the same time. In the
intermediate forming process, the 3’-hydroxyl group of DNA leaves the DNA
backbone, and the active site tyrosine of type IA and type IIA topoisomerases
covalently links to the 5’-phosphate to form a phosphotyrosyl bond (Pommier,
2013). Whereas the active site tyrosine of type IB topoisomerase attacks the
phosphate of the DNA group to form a 3’-phosphotyrosyl bond (Pommier, 2013;
Wang, 2002).
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Figure 1 | Catalysis of transient breakage of DNA by DNA
topoisomerases.
Transesterification
enzyme
Figure
I.6 Catalysis of transient
breakage of DNAbetween
by type IAan
DNA
topoisomerases
(Wang,
2002).
tyrosyl and a DNA phosphate group leads to the breakage of
a DNA backbone bond and the formation of a covalent
enzyme–DNA intermediate. Rejoining of the DNA backbone
by the reversal of the reaction shown. In the
I.4.2bond
Typeoccurs
II topoisomerases
reaction that is catalysed by a type IA or a type II enzyme,
Type II topoisomerases are essential enzymes for all organisms. Type IIA
a 3′-OH
is the leaving group and the active-site tyrosyl
becomes covalently
linked DNA
to a 5′-phosphoryl
group,IVasand eukaryotic
topoisomerases
include bacterial
gyrase, topoisomerase
depicted. In the reaction that is catalysed by a type IB enzyme
topoisomerase II. They cleave double-strand DNA in a DNA duplex and process
(not shown), a 5′-OH is the leaving group and the active-site
tyrosyl
covalently
to a2013).
3′-phosphoryl
DNA
strandbecomes
passage (Gentry
and linked
Osheroff,
All Type IIgroup.
topoisomerases
can catenate/decatenate, knot/unknot circular duplex DNA, and relax positively
and negatively supercoiled DNA (Figure I.7). They are important for maintaining

Reactions catalysed by topoisomerases
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of the
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Topoisomerase
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two kinds of
of double-stranded (ds)DNA is first unpaired by the
binding of the enzyme, and a transient break is
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type IIA topoisomerases (Gentry and Osheroff, 2013). Topoisomerase IIα is
involved in the survival of proliferating cells during the cell cycle. The enzyme
topoisomerase IIβ participates in the neural development.

Type IIA

topoisomerases are clinical therapeutic targets for anticancer and antibacterial
drugs.

These drugs include poison and catalytic inhibitors (Nitiss, 2009).

Quinolones are broad-spectrum antibacterial drugs.
antituberculosis drugs.
gyrase.

As well as first line

Quinolones are poison inhibitors, which target DNA

Amsacrine, etoposide, and doxorubicin are poison anticancer drugs,

which target human type II topoisomerases (Pommier et al., 2010).
DNA Topoisomerases

Figure 2 Reactions performed by type II topoisomerases. Examples of specific type II topoisomerases that catalyze the indicated reactions are
given above the arrows. It is important to note that in the decatenation/catenation reaction, the plasmids may be supercoiled before decatenation/
catenation occurs; for illustrative purposes they have been drawn as relaxed. Although only relaxation of negative supercoils is shown, all known
type II topoisomerases can relax positively supercoiled DNA as well. (Redrawn from reference 313 with permission of the publisher.) doi:10.1128/
ecosalplus.ESP-0010-2014.f2

Figure I.7 Catalytic reactions of type II topoisomerases (Bush et al., 2015)
DNA supercoiling can be either positive (corresponding to over-twisting of the helix) or negative (corresponding to under-twisting of the helix). The binding
of proteins to DNA is often dependent on the DNA
being negatively supercoiled; initiation of the replication of bacterial plasmids requires negative supercoiling
to facilitate the unwinding of the origin sequence (8).
As DNA replication proceeds, positive supercoils are
generated ahead of the replication fork and so-called
precatenanes may build up behind it (Fig. 3) (9). The
supercoils are removed by topoisomerases to prevent excess supercoiling and the breakdown of the replication
machinery.

When two replication forks converge at the end of DNA
replication, catenated DNA rings can be formed if the
daughter molecules are interwound; i.e., precatenanes are
converted to catenanes (Fig. 4) (10, 11). These rings can
be separated by decatenation, in which one DNA ring is
cleaved and the other ring is passed through the doublestrand break. As discussed below, this situation can be
resolved by the activities of various topoisomerases.
may also result in changes to DNA topol13Transcription
ogy, for example, if the DNA is anchored to a fixed point
in the cell. It has been proposed that during transcription DNA rotates on its axis to allow RNA polymerase
3
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Type II topoisomerases function as homo-dimers. Eukaryotic type II
topoisomerases are dimeric (A2), and prokaryotic type II topoisomerases are
tetrameric (A2B2) (Berger and Wang, 1996).

Yeast type II topoisomerase is

(BA)2 homo-dimers. Type II topoisomerases have three interfaces, N-gate, DNAgate, and C-gate (Figure I.8). The catalytic process of type II topoisomerases is
ATP-dependent. Briefly, they bind a double-stranded DNA (G segment), cleave
it and let the second double-stranded DNA (T segment) through the cleaved
double-stranded DNA.

Two ATP molecules are required for the hydrolysis

process (Gentry and Osheroff, 2013). Magnesium is also needed for catalysis.
The enzyme DNA gyrase is bacterial topoisomerase II (Lee et al., 2012). Two
GyrA and two GyrB subunits form the DNA gyrase. Escherichia coli DNA gyrase
is about 400 kDa. The GyrB and GyrA subunits of DNA gyrase are homologous
to the N- and C-terminal halves of eukaryotic topoisomerase II, respectively. The
tyrosine active site of DNA gyrase is in the GyrA subunit. ATP molecule binds to
N-terminal of eukaryotic topoisomerase II and GyrB subunit of DNA gyrase.
There are identified as ATPase domains, which use ATP binding and hydrolysis
to promote strand passage mechanism in S. cerevisiae topoisomerase II
(Schmidt et al., 2012).
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Fig. 2. Recent structures illuminate the architectures of gyrase and related type II topoisom
map of the
T. thermophilus
gyraseofholoenzyme
complex
with 155 bp(Basu
DNA,
a
Figure
I.8 Crystal structure
S. cerevisiaeintype
II topoisomerase
et ciprofloxacin,
al.,
from [21]).
The
domain
architecture
can
be
seen
together
with
density
attributable
to
DNA
wr
2016).
Crystal structures of protein components and modeled DNA duplex (green) have been fit to the d
is shown in a domain-swapped configuration first observed in (b) a crystal structure (reproduce
enzyme S. cerevisiae topo II in complex with G-segment DNA (green) and AMPPNP. The DNA
I.4.3 Type I topoisomerases
also seen in closed configurations in these structures.
All organisms contain at least one type I topoisomerase. They have the
ability to relax, unknot/knot or decatenate/catenate single-stranded DNA or
double-stranded nicked DNA with a gap in one of the strand (Figure I.8) (Forterre
and Gadelle, 2009). Type I topoisomerases include type IA topoisomerase, type
IB topoisomerase and type IC topoisomerase. Type IA topoisomerase can relax
negatively supercoiled DNA.

Type IB topoisomerase relaxes positively and

negatively supercoiled DNA.

Type I topoisomerase requires Mg2+ in the

relaxation process.
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Bush et al.

reaction. The reactions performed by DNA topoisomerases are depicted in Fig. 1 and Fig. 2. It should be pointed
out that many enzymes (e.g., ligases and recombinases)
can affect DNA topology but are not referred to as topoisomerases, which is a term reserved for enzymes whose

specific role is manipulation of DNA topology. Similarly,
there may be enzymes currently classified as topoisomerases (e.g., topoisomerase III [topo III] and reverse
gyrase) whose principal cellular function may be another
activity.

Figure 1 Reactions performed by type I topoisomerases. Examples of specific type I topoisomerases that catalyze the indicated reactions are
given above the arrows. It is important to note that in the decatenation/catenation reaction, the non-nicked plasmid may be supercoiled before
decatenation/catenation occurs; for illustrative purposes it has been drawn as relaxed. (Adapted from reference 313 with permission of the
publisher.) doi:10.1128/ecosalplus.ESP-0010-2014.f1

Figure I.9 Catalytic reactions of type I topoisomerases (Bush et al., 2015)
2
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Type IB topoisomerases are present in all eukaryotic organisms. Animal
virus topoisomerase I and mammalian mitochondrial topoisomerase I belong to
the type IB topoisomerase family (Patel et al., 2010). Type IB topoisomerases
relax duplex DNA by a “controlled rotation mechanism’’. They nick a singlestranded DNA and allow the DNA strands to rotate around each other (Forterre
et al., 2007). Type IB topoisomerases participate in replication, transcription,
repair, and chromatin modification processes. They also target anticancer drugs
including topotecan and irinotecan (Capranico et al., 2017).
Type IA topoisomerases regulate DNA topology by a cleavage and strand
passage mechanism. During the cleavage and religation process, one single
strand of DNA is cleaved, and the other single strand of DNA pass the gap at the
strand break. A covalent intermediate of DNA and enzyme forms in the cleavage
process and disappears in the religation process. There is a conformational
change of the enzyme during this process (Figure I.10). The type IA subfamily
include bacterial DNA topoisomerase I, bacterial DNA topoisomerase III,
eukaryotic DNA topoisomerase III and reverse gyrase (Table I.2). Bacterial type
IA topoisomerases are classified to relax only negatively supercoiled DNA with
Mg2+ requirement.

As type IA topoisomerase, bacterial topoisomerase I is

considered as a potential target for antibacterial drugs (Tse-Dinh, 2009).

17

Figure 2 Proposed mechanism of DNA relaxation catalysed by type IA topoisomerases
Proposed mechanism employed by type IA enzymes to relax DNA [10,14]. The conformations of many of the different
intermediates are based on solved structures, but some intermediates have not been observed and remain hypothetical.
Many of the features of the proposed mechanism have been confirmed through biochemical, structural and single-molecule
experiments. ssDNA, single-stranded DNA.

Figure I.10 Proposed mechanism of type IA topoisomerase (Terekhova et al., 2013)
in different cellular processes. In vivo, a major function details by the inevitable averaging that occurs when looking at
of topoisomerase I, together with two type II enzymes billions of molecules at a time. For this reason, it is important
In type IA topoisomerases, the tyrosine active site is in the NTD. The N(topoisomerase IV and gyrase), is to maintain the supercoiled to look at the action of topoisomerases at the single-molecule
state of DNA in the cell [21]. The function of topoisomerase level. Single-molecule studies of type I topoisomerases have
terminal domain of type IA topoisomerase has the DNA binding, cleavage and
III, the other type IA enzyme, is to resolve single-stranded been very informative and have helped to uncover new aspects
DNA recombination and replication intermediates [22–27], of the mechanism of these enzymes [33]. Type IA enzymes
religation activity.
The N-terminal domain of type IA topoisomerases is
and, in some instances, double-stranded intermediates [28]. were among the first topoisomerases to have been studied
These differences in functions are reflected in their in vitro at the single-molecule level, and these studies confirmed
conserved within bacterial topoisomerases and includes the topoisomerasecharacteristics: topoisomerase I is a better DNA relaxation the enzyme-bridged strand passage mechanism [19]. More
enzyme than topoisomerase III [22], whereas topoisomerase recently, studies of eukaryotic type IB topoisomerases
primase domain (TOPRIM) (Aravind et al., 1998). However, the CTD is variable
III is a better decatenating enzyme [29,30]. From a structural revealed some of the constraints imposed by the protein
perspective, the two enzymes are also different in subtle on the swivelling of the DNA strands and also helped us
within bacterial species (Figure I.11). Escherichia coli topoisomerase I (EcTOP I)
ways. The major difference between the two is the presence to understand the role of some topoisomerase poisons [34–
essential to clarify
of a much larger C-terminal domain in topoisomerase I 36]. Finally, single-molecule studies were
2+
contains
three
tetracysteine
zinc
ribbon
motifs
in
its
CTD.
These
Zn
binding
that is involved in DNA binding and is essential for DNA the mechanism of topoisomerase V, the sole member of the
relaxation activity [11,12], whereas the C-terminal domain type IC group [37].
domains include Cys-X -Cys-Gly-X2-Met-X
-Cys-X4-10-Cysthesequence
(TseIn12-13
order to understand
mechanistic difference between
of topoisomerase III also binds DNA, but2 is smaller and
dispensable [31]. Another small, but significant, difference is the two E. coli type IA topoisomerases, we analysed DNA
Dinh and Beran-Steed, 1988). The Zinc ribbon motifs are essential for the
the presence in topoisomerase III of a 17-amino-acid region, relaxation by the two enzymes at the single-molecule level
termed the decatenation loop, that resides at the base of using a magnetic tweezers set-up [38]. In this type of
activity of E. coli topoisomerase I are proposed to bind to DNA and facilitate
the central hole and whose removal decreases decatenation experiment, one end of a long single DNA molecule is
attached to a functionalized glass slide while the other end
activity markedly [32].
stand passage. If these cysteine amino
acids are mutated, EcTOP I loses
is attached to a small (∼1–3 µm) paramagnetic bead. By
using a rotating magnet, it is possible to introduce supercoils
into the DNA at will while monitoring the position of the
Single-molecule studies of type IA
18bead through a microscope. Rotating the magnet causes the
topoisomerases
Biochemical experiments have been instrumental to study DNA to over- or under-wind, and eventually plectonemes
topoisomerases and to understand their differences and are formed in the single DNA molecule [39]. This is always
similarities. Nevertheless, experiments in bulk can hide some the case for positively supercoiled or overwound DNA,

activity. Streptomyces topoisomerase I CTD contains lysine repeats and end with
acidic amino acids. Other bacterial topoisomerase I also contain lysine repeats
with different position and sequence length (Strzalka et al., 2017). The lysine
repeats in Streptomyces topoisomerase I are able to stabilize the topoisomeraseDNA complex and maintain the enzyme processivity. The CTD in Streptomyces
topoisomerase I is responsible for DBA binding and the cellular growth of
Streptomyces.

Figure I.11 Comparison of topoisomerase I sequences from various bacterial
species. N-terminal domain (blue); C-terminal domain (red); TOPRIM domain (purple) is
conserved in NTD; the catalytical tyrosine residue (black); Zinc ribbon motifs (yellow);
lysine repeats (red) (Strzalka et al., 2017).
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I.4.4 The cellular function of DNA topoisomerases
DNA topoisomerases affect DNA replication, transcription, recombination,
and repair at the cellular level (Chen et al., 2013; Wang, 2002). It is reported that
DNA topoisomerases play an important role in all the steps of replication, in
initiation, elongation, and termination (Wang, 2002).

In E. coli, DNA

topoisomerase III’s strand passage function controls the DNA recombination
mechanism (Harmon et al., 1999).

The replication process is initiated from

specific supercoiled origins in both eukaryotes and prokaryotes (Wu et al., 2014).
Eukaryotes activate replication by loading origin recognition complex to
chromatin (Parker et al., 2017).

Topoisomerases are needed to work with

specific origins to control replication initiation (Magnan and Bates, 2015;
Rampakakis et al., 2010; Vos et al., 2011).

In the DNA elongation step,

replicative helicase progress brings overwinding and potential distortion positive
helical stress to the DNA duplex.

In the eukaryote, type II and type IB

topoisomerases are able to remove positively supercoiled DNA ahead of the
replication fork (Keszthelyi et al., 2016). Topoisomerase III is also observed to
support the nascent chain elongation during DNA replication in E. coli (Hiasaand
and Marians, 1994).

The new precatenanes are resolved by type II

topoisomerases (Figure I.12).

If two replication forks are too close, the two

precatenates form a hemicatenane. Topoisomerase III is able to resolve this
topological state with RecQ and stablilize the DNA topology (Nurse et al., 2003;
Suski and Marians, 2008). In yeast cells, topoisomerase II mediated replication
termination by segregation of chromosomes (Bailey et al., 2015; Dinardo et al.,
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1984; Fachinetti et al., 2010).
The enzyme RNA polymerase and its bounded proteins regulate
transcription process. In the elongation step of transcription, the DNA topology is
dynamic and stressful. Positive DNA supercoiling is generated ahead of the
elongating RNA polymerase, and negatively supercoiled DNA is released or
rearranged behind the transcription company (Kouzine et al., 2014). The DNA
topoisomerases are required to stabilize the DNA topology and remove the
topological stress by interacting with DNA (Keszthelyi et al., 2016). In E. coli,
gyrase is observed to bind positively supercoiled DNA to start transcription
(Chong et al., 2014). In eukaryotic cells, Type IB and type II topoisomerases are
able to remove positively supercoiled DNA in this step. Both type I and type II
topoisomerase are able to relax the negatively supercoiled DNA for transcription
elongation (Vos et al., 2011; Wang, 2002). A current study shows that DNA
topoisomerase I interacts with RNA polymerase via a 27 amino acid tail in its
CTD in M. smegmatis (Banda et al., 2017). These interactions enable DNA
topoisomerase I in M. smegmatis to work with RNA polymerases in the
transcription process.
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Figure I.12 Topoisomerase function in replication elongation. (Vos et al., 2011)

I.5 Bacterial topoisomerase I
I.5.1 E. coli type IA topoisomerases
Escherichia coli topoisomerase I is the first discovered and well-studied
topoisomerase. The 67 kDa NTD of EcTOP I is required in its DNA cleavage and
religation activity (Ahumada and Tse-Dinh, 2002).
could interact with EcTOP I.

Both ssDNA and dsDNA

It was also observed to have catenation and

decatenation activity (Ahumada and Tse-Dinh, 2002; Terekhova et al., 2014).
The NTD of EcTOP I contains active site and DNA interaction region with active
site tyrosine (Y319) and TOPRIM motif (Narula and Tse-Dinh, 2012). Without
the DxD TOPRIM motif, the Mg2+ binding ability of EcTOP I decreased (Cheng et
al., 2009). The TOPRIM mutation affected religation activity. Thus the DNAtopoisomerase covalent complex was trapped. As a Zn2+ binding protein, the
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CTD of EcTOP I contains three repetitive Zinc ribbon domains (Lu et al., 2011;
Tse-Dinh and Beran-Steed, 1988). The C-terminal domain of EcTOP I binds to
ssDNA but not dsDNA. It also interacts with RNA polymerase in transcription
process (Cheng et al., 2003). The crystal structure of EcTOP I with ssDNA
revealed that the Zinc ribbon motifs bind to ssDNA (Figure I.12) (Tan et al.,
2015). As mentioned, E. coli topoisomerase III (EcTOP III) plays an important
role in DNA recombination. Escherichia coli topoisomerase III catenates
covalently closed DNA and interacts with helicase (Harmon et al., 2003).
Escherichia coli topoisomerase III also decatenates catenated both dsDNA and
ssDNA with RecQ (Suski and Marians, 2008). Kinetic studies revealed that the
decatenation activity of EcTOP III is more efficient than that of EcTOP I
(Terekhova et al., 2014). Escherichia coli topoisomerase III contains a
decatenation loop in its CTD. While EcTOP I is more efficient for DNA relaxation
(Terekhova et al., 2012). Different structures of these two topoisomerases lead
to different pathways in their catalytic activities. The NTD is conserved (Figure
I.13).

Subdomain I contains the TOPRIM motif. Active site tyrosine is in

subdomain III (D3). Unlike EcTOP I, EcTOP III has a short CTD without Zn2+
binding domains (Terekhova et al., 2013).
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Figure 1. Structure of full-length E. coli topoisomerase I (EcTOP1) in
complex with single-stranded DNA (ssDNA). (A) Domain arrangement
of E. coli topoisomerase I. Between D8 and D9, there is a helical hairpin. (B) A ribbon diagram of full-length EcTOP1 in complex with ssDNA.
Full-length EcTOP1 includes four N-terminal domains: D1 (deep salmon),
D2 (orange), D3 (cyan) and D4 (green); and five C-terminal domains: D5
(pink), D6 (yellow), D7 (red), D8 (lime) and D9 (grey). The helical hairpin
between D8 and D9 is colored in wheat. A ssDNA that binds to the Cterminal domains is colored in blue. Each Zn(II) is represented as a gray
sphere. The secondary structures of D2 and part of D4 and D6 are labeled for discussion purposes. A part of the loop (colored in green) between !2 and "6 of D2 includes a charged and conserved sequence of
R442KGDEDR, which is highly flexible and was not observed in earlier
TOP67 structures. Figures 1B, 2, 4 and 7A are prepared with the program
PyMOL (http://www.PyMOL.org).

Figure I.13 Structures of EcTOP I and EcTOP III. (A) The organization of EcTOP I and EcTOP III. (B) The crystal
structure of EcTOP III. (C) The crystal structure of EcTOP I and DNA complex (Schoeffler and Berger, 2008; Tan et
al., 2015)
Fig. 6. Type IA topoisomerase organization and structure. (a) The primary domain structures of E. coli
topoisomerase I and III (type IA topoisomerases). Domains are indicated by color and labeled catalytic
residues are shown as black bars. (b) Structure of E. coli topoisomerase III complexed with DNA. Domains
are colored as in (a). Bound DNA is colored by atom and shown as sticks. The catalytic tyrosine (Y, cyan
sphere) is located at the domain III–domain I interface. (PDB ID 1I7D) (Changela et al. 2001). (c) Rotation
of the structure in (b) by 90x reveals the decatenation loop projecting from the ‘ back ’ of the enzyme. (PDB
ID 1I7D) (Changela et al. 2001). (d) Close-up view of the E. coli topo III active site in the absence of DNA.
Protein is colored by domain as in (b). The active site tyrosine forms hydrogen bonds with two conserved
aspartates (PDB ID 1D6M) (Mondragon & DiGate, 1999). (e) Close-up of the active site of E. coli topoisomerase III bound to DNA in a ‘ pre-cleavage ’ conformation. Protein is colored as in (b). DNA is colored
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served. The conformation of the active site of the enzyme,
which includes residues D111, D113, Y319 and R321 from
D1 and D3 are essentially the same (Supplementary Figure S2). However, if all four N-terminal domains were used
for an alignment, the RMSD value is as high as 1.84 Å,
which indicates domain-domain movements between the
two structures. Therefore the presence of the C-terminal domains with bound ssDNA may have an effect on the conformation of the toroid formed by the N-terminal domains.
The largest change involves D2 that rotates (∼14◦ ) away
45 8 4
from the N-terminal domains’ toroidal plane (Supplementary Figure S3).
A loop between the !2 helix and the "6 strand of D2,
which was mostly disordered in previous TOP67 structures,
can now be observed in this structure (Figure 1). The flex-
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I.5.2 Mycobacterial topoisomerase I
There is only one type I topoisomerase in mycobacteria.
Mycobacterium tuberculosis DNA topoisomerase I is validated as a target
for TB therapy (Nagaraja et al., 2017). The challenge of the study of M.
tuberculosis is that it is an infection and slow-growing bacteria. But M.
smegmatis growth is faster than M. tuberculosis; it serves as a noninfection model to study M. tuberculosis DNA topoisomerase I from M.
smegmatis MC2155 contains 936 residues (MsTOP1), and DNA
topoisomerase I from M. tuberculosis H37RV contains 934 residues
(MtTOP1). Previous studies revealed that MtTOP1 is essential for the cell
survival of M. tuberculosis (Ahmed et al., 2014). Mycobacterial
topoisomerase I is essential for maintenance of cellular phenotype, cell
growth characteristics and gene expression in mycobacteria (Ahmed et
al., 2014; Ahmed et al., 2015).
Mycobacterium

smegmatis

DNA

topoisomerase

I

and

Mycobacterium tuberculosis DNA topoisomerase I were both reported to
have the DNA cleavage, religation, binding, relaxation and catenation
activities (Bhaduri et al., 1998). The NTD of mycobacterial topoisomerase
I is sufficient for the DNA binding, DNA cleavage and religation steps, but
requires CTD for relaxation of negatively supercoiled DNA (Jain and
Nagaraja, 2006). Both NTD and CTD of MsTOP1 could bind to ssDNA
and dsDNA, but NTD of MsTOP1 can bind specific and nonspecific DNA
(Jain and Nagaraja, 2006). Mycobacterial topoisomerase I proteins have
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no Zn2+ binding domains in their CTD (Jain and Nagaraja, 2006).

A

recent study reported that the CTD of MsTOP1 contains three highly
conserved stretches of basic amino acids. These basic amino acids are
involved in DNA binding and promotion of strand passage mechanism
(Ahmed et al., 2013). Depletion of these basic amino acids lead to the
loss of catalytic activity and affect the growth of M. smegmatis. Besides,
Dr. Nagaraja’s study revealed that wild-type MsTOP1 and mutant enzyme
with deletion of stretch 1(KKGKK) could bind two DNA molecules (Ahmed
et al., 2013). Dr. Nagaraja revealed that MsTOP1 contained two DNA
binding sites, one is in NTD and another is in CTD.

A recent study

showed metal binding amino acids (D108 and E112) in MtTOP1 (Godbole
et al., 2015).

I.6 Overview of the study
Type

IA

topoisomerases

are

essential

in

all

organisms.

Mycobacterial topoisomerase I is the important enzyme for mycobacteria.
It plays important roles in DNA replication, transcription and recombination
process. It is required in mycobacteria cellular growth, phenotype, gene
stability and expression. However, the exact structure and mechanism of
mycobacterial topoisomerase I remain to be fully elucidated. The NTD’s
function is conserved within type IA topoisomerases, but the CTD’s
sequence and domain organization of mycobacterial topoisomerase I are
different from other type IA topoisomerases, such as EcTOP I and EcTO
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III. Hence, the overall goal of this study is to reveal the structure and
mechanism of mycobacterial topoisomerase I with X-ray crystallography
and biochemical catalytic activity analysis.
The first aim of the current study is to determine the effects of
deletion

of

proposed

C-terminal

subdomains

on

mycobacterial

topoisomerase I activity. The CTD of mycobacterial topoisomerase I could
be divided into four subdomains and a C-terminal tail.

The catalytic

activity assays are carried out to study the function of each subdomain at
the molecular level. The second aim of the study is to determine the
crystal structure of deletion mutants, and the catalytic roles of conserved
amino acid residues in the active site of mycobacteria topoisomerase I.
Crystal structures of MtTOP1 were obtained.

The crystal structures

revealed that certain conserved amino acids are required for DNA binding
or divalent ion interaction. Conserved amino acids include MtTOP1 E24
and MsTOP1 E21, were studied.
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CHAPTER 1: MECHANISM AND FUNCTION OF SUBDOMAINS IN
MYCOBACTERIAL TOPOISOMERASE I C-TERMINAL DOMAIN

ABSTRACT
DNA topoisomerase I is an essential enzyme for eukaryotes and
prokaryotes. Mycobacterial topoisomerase I overcomes the topological
problems of chromosomes in mycobacteria and maintain the growth of
mycobacteria.

The NTD of mycobacterial topoisomerase I contain the

active site for DNA binding, cleavage and religation. The CTD of
mycobacterial

topoisomerase

I

(Mycobacterium

tuberculosis

topoisomerase I and Mycobacterium smegmatis topoisomerase I) can be
divided into four subdomains (D5-D8) and a positively charged tail. Each
subdomain has a GxxGPY sequence motif. The current study shows the
involvement of subdomains in catalysis of different reactions by
mycobacterial topoisomerase I. Subdomains D8 and D7 are required for
maintaining the relaxation activity of mycobacterial topoisomerase I.
Subdomain D5 in the absence of the other C-terminal subdomains is
sufficient for the DNA cleavage, religation, catenation and decatenation
activity.
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INTRODUCTION
Tuberculosis (Rosenbaum et al.) is a global infectious disease. It
has infected about one-third of the world’s populations. The World Health
Organization reported 6.3 million new cases of TB in 2016 (WHO, 2017).
Multidrug-resistance TB (MDR-TB) is a global problem for TB treatment
(Mishra et al., 2015). As a top cause of death from the infectious disease,
more efficient treatment for TB and MDR-TB is an urgent need.
Tuberculosis is caused by various strains of mycobacteria, usually
Mycobacterium tuberculosis (M. tuberculosis) (Veatch and Kaushal,
2017).
DNA topoisomerases are ubiquitous in both eukaryotes and
prokaryotes. They are involved in DNA replication, recombination,
transcription, and repair processes.

They are essential enzymes that

could regulate DNA topology for optimal growth of eukaryotic and
prokaryotic organisms (Vos et al., 2011).

There are two types of

topoisomerases, type I topoisomerase (Topo I) and type II topoisomerases
(Topo II) (Bush et al., 2015). Type I DNA topoisomerases cleave and
rejoin a single strand of DNA. There are three sub-types of type I
topoisomerases, topoisomerase IA, topoisomerase IB and type IC
topoisomerase (Chen et al., 2013). The enzymes of type IA subfamily
include bacterial DNA topoisomerase I, bacterial DNA topoisomerase III,
eukaryotic DNA topoisomerase III and reverse gyrase (Tse-Dinh, 1998).
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Type I topoisomerases can relax supercoiled DNA and type IA
topoisomerases are classified to relax only negatively supercoiled DNA
with Mg2+ requirement.
topoisomerases,

In mycobacteria, there are two types of

mycobacterial

topoisomerase

I

and

gyrase.

Mycobacterial topoisomerase I and E. coli topoisomerase I both belong to
the type IA topoisomerase family. The bacterial topoisomerase I can bind
and cleave single-stranded DNA. It also has the ability to unknot/knot or
decatenate/catenate single-stranded DNA circles or double-stranded DNA
circles with a nick (Bugreev and Nevinsky, 2010). The NTD of type IA
topoisomerase I are conserved, but the CTD can be found with a variety in
size and sequence (Strzalka et al., 2017; Viard and de la Tour, 2007).
The CTD of E. coli topoisomerase I contains three tetracysteine Zinc
ribbon motifs. These Zinc ribbon motifs are specified by Cys-X2-Cys-GlyX2-Met-X12-13-Cys-X4-10-Cys sequence (Tse-Dinh and Beran-Steed, 1988),
and are essential for the relaxation activity of E. coli topoisomerase I. It
has been proposed that the Zinc ribbon motifs bind to single-stranded
DNA and facilitate DNA stand passage (Ahumada and Tse-Dinh, 2002).
Mycobacterial topoisomerase I is essential for maintenance of the
phenotype, growth and gene expression in mycobacteria (Ahmed et al.,
2014; Ahmed et al., 2015). Mycobacterium tuberculosis topoisomerase 1
(MtTOP1) is validated as a potential target for anti-tuberculosis therapy
(Ravishankar et al., 2015; Tse-Dinh, 2009). In MtTOP1, the active site
Tyr342 is in the NTD (Tan et al., 2016).
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The NTD of M. smegmatis

topoisomerase I (MsTOP1) is required during the DNA cleavage and
religation steps (Jain and Nagaraja, 2006).

The CTD of MsTOP1 is

proposed to be required for interaction with the passing strand of DNA
(Ahmed et al., 2013). We hypothesize that mycobacterial topoisomerase I
C-terminal has repeated motifs distinct from the Zinc ribbon motifs that
play the important function in catalysis. Deletion mutants (Figure1.1) were
unstructured to examine the roles of the individual subdomains. To study
the CTD of mycobacterial topoisomerase I, the CTD was divided into four
subdomains and a positively charged tail (Figure1.1, Table1.1).

Each

subdomain contains a GxxGPY sequence motif. Our structure studies
showed that each subdomain comprises of four β-strands and one Cterminal α-helix (Figure 1.2) (Tan et al., 2016)
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structures did not express well as soluble proteins. In a
recently determined structure of full-length EcTOP1 in
complex with single-stranded DNA (ssDNA) [9] (PDB
ID: 4RUL), the C-terminal region of EcTOP1 comprises
three 4-Cys zinc ribbon domains and two zinc
ribbon-like domains, and a modular ssDNA-binding
mode was observed. This suggests that the C-terminal
region of MtTOP1 may also contain multiple domains
with repeated and conserved sequence motifs even
though the sequences of EcTOP1 and MtTOP1
C-terminal regions are very different with essentially
no homologies. We analyzed the structural aspects of
the C-terminal region of MtTOP1. The recognition of
individual domains in this region helped us redesign
constructs for functional studies and enabled us to
obtain diffraction-quality crystals for structural characterization of MtTOP1. We report here the crystal
structure of MtTOP1-704t with the N-terminal domains
D1–D4 and the C-terminal domain D5 (amino acids
A2–T704) and its functional characterizations.

prediction, one is a part of the insertion on the loop
between the β3 and β4 strands of D6, and the other one
is a part of the linker between the D7 and D8 domains
(Fig. 1). Deletions of the stretches of basic amino acids
in the C-terminal region of MtTOP1 have been shown
to affect DNA binding and DNA strand passage [13].
The deletions would unlikely make an impact on the
folding of the individual C-terminal domains but may
affect the relative orientations of the C-terminal
domains and the interdomain flexibility.
MtTOP1-704t is one of the constructs that have been
made based on the C-terminal domain prediction
mentioned above. It spans from amino acid A2 to
amino acid T704 and includes the N-terminal domains
and the first predicted C-terminal domain D5 (Fig. 1
and Graphical Abstract). The functional and structural
characterization of MtTOP1-704t is the focus of this
study.
Biochemical activities of MtTOP1-704t
MtTOP1-704t can be expressed readily as a

Results
Figure

1.1 The subdomain organization
of recombinant
mycobacterial
soluble
protein intopoisomerase
E. coli host strain T7I.
The CTD mutants of mycobacterial topoisomerase
are was
constructed
with
Express Crystal. TheIprotein
purified to N99%
deletions
of
D5,
D6,
D7
and
D8
subdomain.
Analysis of C-terminal domains of MtTOP1
homogeneity and assayed for relaxation of nega-

MtTOP1 does not have easily recognizable sequence motifs (such as the repeated 4-Cys Zn-binding
motifs present in EcTOP1) that can help divide the
MtTOP1 C-terminal region into domains. Nevertheless,
MtTOP1 does bear four GxxGPY sequence motifs [10]
in its C-terminal region. Based on the locations of
the four GxxGPY repeats, we divided the region into
four repeat domains (Fig. 1). A secondary structure

tively supercoiled plasmid DNA. The results in Fig. 2
showed that, while relaxation activity can be
detected with 6.2 ng (60 fmol) of the full-length
MtTOP1, relaxation activity was not observed with
100 ng (1.3 pmol) of MtTOP1-704t.
Although relaxation activity could not be detected
for MtTOP1-704t, the protein was found to have DNA
cleavage activity similar to that of full-length MtTOP1
(Fig. 3a). The same preferred cleavage site with a

Fig. 1. Division of the C-terminal region of M. tuberculosis topoisomerase I into four domains and a flexible tail. The
conserved residues among the four domains are highlighted in red, including the GxxGPY sequence motif. Besides the
Figure
1.2 residues
Division
C-terminal
of M. tuberculosis
conserved
tyrosine
withinofthethe
GxxGPY
motifs, otherdomain
possible DNA-binding
residues are highlighted in magenta
I in
four
subdomains
a flexible
The
conserved
(fortopoisomerase
possible π-stacking to the
bases
of nucleotides)
or blue (forand
possible
π-cation or tail.
salt bridge
or hydrogen
bond to DNA).
Theresidues
secondary structures
of
D5
are
indicated
above
the
appropriate
sequence
of
D5.
The
highly
positively
among the four subdomains are highlighted in red, including thecharged tail
afterGxxGPY
D8 is listed sequence
below the alignment,
motif.and it is presumably structurally flexible.
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NTD+D5+D6

NTD+D5+D6

NTD+D5+D6+D

NTD+D5+D6

NTD+D5

+D7+D8+tail

+D7+D8

7

Mycobacterium

MtTOP1

MtTOP1-910t

MtTOP1-840t

MtTOP1-786t

MtTOP1-704t

tuberculosis

(2-934)

(2-910)

(2-840)

(2-786)

(2-704)

MsTOP1

MsTOP1-909t

MsTOP1-839t

MsTOP1-785t

MsTOP1-701t

(1-936)

(2-909)

(1-839)

(1-785)

(1-701)

topoisomerase I
(MtTOP1)
Mycobacterium
smegmatis
topoisomerase I
(MsTOP1)
Table 1.1 The construction of wild-type and mutant recombinant mycobacterial topoisomerase I clones that
include the residues shown in the brackets.
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MATERIALS AND METHOD
Construction of plasmids and clones
The M. smegmatis topA gene was cloned from M. smegmatis
MC2155. The genomic DNA was purified from M. smegmatis MC2155 with
Quick-DNA Fungal/Bacterial Kit (Zymo Research). The M. tuberculosis
topA gene was cloned from M. tuberculosis H37RV. Mycobacterium
tuberculosis H37RV genomic DNA was provided by BEI resources. The
polymerase chain reaction (PCR) was used to amplify wild-type and
mutant mycobacterial topoisomerase I coding sequence. The MsTOP1
plasmid was constructed with the Gibson Assembly method to insert the
MsTOP1 gene into a pET-His6-Mocr TEV-LIC cloning vector (2O-T). The
2O-T MtTOP1 plasmid was constructed in our lab (Annamalai et al.,
2009). NEBbuilder HIFI DNA Assembly method was used to insert coding
sequence for MsTOP1-909t and MtTOP1-910t into the 2O-T vector.
MsTOP1-839t, MsTOP1-786t, MsTOP1-701t, MtTOP1-840t, MtTOP1786t, MtTOP1-704t were cloned by site directed mutagenesis to substitute
a stop codon in the 2O-T MsTOP1 and 2O-T MtTOP1 plasmid. The
primers (from Sigma Genosys) used for cloning are listed in Table 1.2.
(IBC-16-009-CR02)
In the construction of 2O-T MsTOP1, the linear 2O-T plasmid was
amplified using the Q5 High-Fidelity DNA Polymerase (New England
Biolabs) and 2O-T plasmid as template (35 cycles of 98°C for 30 sec,
70°C for 30 sec, 72°C for 3.5 min). M. smegmatis MC2155 genomic DNA
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was used as the template to amplify MsTOP1 coding gene with Q5 Hot
Start High-Fidelity DNA Polymerase (35 cycles of 98°C for 30 sec, 72°C
for 3 min).

After PCR reaction, the PCR products were purified by

electrophoresis in 1% agarose gel with Tris-acetate-EDTA buffer (TAE, 40
mM Tris, 20 mM acetic acid, and 1 mM EDTA). The gels were stained
with 1 µg/mL concentration ethidium bromide for 1 hour and photographed
over UV light. The PCR products were purified from the excised gel slice
with GeneJET PCR Purification Kit (Thermo Scientific).

Purified PCR

product MsTOP1 (0.45 pmol ) and 2O-T (0.14 pmol) (the ratio is 3:1) were
incubated with Gibson Assembly Master Mix (New England Biolabs) at
50°C for 15min.

Assembled product was transformed into NEB turbo

competent cells (New England Biolabs). The transformants were plated
on LB + 100 µg/ml carbenicillin + 2% glucose plates and incubated at
37°C overnight.
In the construction of 2O-T MsTOP1-909t and 2O-T MtTOP1-910t,
the linear 2O-T plasmid was amplified using the Q5 Hot Start High-Fidelity
DNA Polymerase (New England Biolabs).

2O-T MsTOP1 and 2O-T

MtTOP1 plasmids were used as template for 2O-T MsTOP1-909t and 2OT MtTOP1-910t. The PCR reaction to amplify 2O-T MsTOP1-909t used
Q5 Hot Start High-Fidelity DNA Polymerase for 35 cycles of 98°C for 30
sec, 71°C for 30 sec, 72°C for 2.5 min. The PCR reaction to amplify 2O-T
MtTOP1-910t used Q5 Hot Start High-Fidelity DNA Polymerase to react
for 35 cycles of 98°C for 30 sec, 71°C for 30 sec, 72°C for 2 min. After
35

PCR reaction, the PCR products were purified by electrophoresis in 1%
agarose gel with TAE buffer. The gels were stained with 1 µg/mL
concentration ethidium bromide for 1 hour and photographed over UV
light. The PCR products were purified from the excised gel slice with
GeneJET PCR Purification Kit.

Purified PCR product MsTOP1 (0.014

pmol) and 2O-T (0.14 pmol) (the ratio is about 2:1) were incubated with
NEBuilder HiFi DNA Assembly Master Mix (New England Biolabs) at 50°C
for 15 min.

Assembled product was transformed into NEB turbo

competent cells. The transformants were plated in the LB + 100 µg/ml
carbenicillin + 2% glucose plates and incubated at 37°C overnight.
The materials and protocol for site-detected mutagenesis are
described in Table 1.3.

After PCR mutagenesis reactions, the PCR

products were purified by electrophoresis in 1% agarose gel with TAE
buffer.

The template plasmids were digested by treatment with Dpn1

restriction enzyme (New England Biolabs) or KLD mix (kinase, ligase,
DpnI; New England Biolabs). NEB turbo competent cells and NEB 5α
competent cells (New England Biolabs) were used for the transformation
of mutant plasmids. The transformants were plated on the LB + 100 µg/ml
carbenicillin + 2% glucose plates.
Wild-type and mutant plasmids were purified by GeneJET Plasmid
Miniprep Kit (Thermo Scientific). Nucleotide sequencing (Genewiz and
Eurofins genomics) was used to verify the sequence of the complete
coding region of plasmids.
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Primer name
MsTOP1 forward
MsTOP1 reverse
MsTOP1-909t
forward
MsTOP1-909t
reverse
MsTOP1-839t
forward
MsTOP1-839t
reverse
MsTOP1-785t
forward
MsTOP1-785t
reverse
MsTOP1-701t
forward
MsTOP1-701t
reverse
MtTOP1-910t
forward
MtTOP1-910t
reverse
MtTOP1-840t
forward
MtTOP1-840t
reverse
MtTOP1-786t
forward
MtTOP1-786t
reverse
MtTOP1-704t
forward
MtTOP1-704t
reverse
2O-T forward
2O-T reverse

Primer sequence (5’-3’)
GGGATCGAGGAAAACCTGTACTTCCAAATGGCTGGCG
GCGACCG
GCGGATCCGTTATCCACTTCCAATATTGTTCGGCGGA
AACCTAGGCCTTCTT
GGGATCGAGGAAAACCTGTACTTCCAAATGGCTGGCG
GCGACCG
GAGTCCGGACACCTTGGAAGTACAGGTTTTCC
CGGCCACGGCGTTTCTACTCGGCGTAGATCTT
AAGATCTACGCCGAGTAGAAACGCCGTGGCCG
GCCCACGACGCGCTACAGCGACAGCAGC
GCTGCTGTCGCTGTAGCGCGTCGTGGGC
GCGTCCCTCTTGCTATGTGGCGAAGAGCTTTTCGG
CCGAAAAGCTCTTCGCCACATAGCAAGAGGGACGC
GATCGAGGAAAACCTGTACTTCCAATTGGCTGACCCG
AAAACGAAGGG
GCGGATCCGTTATCCACTTCCAATATTGCTAGGCTCG
GCGATCGGCCAA
CCGGCCACGACGTTTCTACTCTGCGTAGATCTTC
GAAGATCTACGCAGAGTAGAAACGTCGTGGCCGG
GCTGTCACTGTAGCGCGTGGTCG
AGCCTCAGCGCGTCTTCG
GTCCCTGTTGCTATGTGGCAAAGAGCTCTTCGGC
GCCGAAGAGCTCTTTGCCACATAGCAACAGGGAC
TTGGAAGTACAGGTTTTCCTCGATCCC
CAATATTGGAAGTGGATAACGGATCCGC

Table 1.2 Primer sequences used for clone construction.
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Plasmid
name

DNA polymerase
Methods and Protocol
Digestion
Transformation
used for cloning
enzyme
competent cells
Phusion Hot Start II
QuickChange site-directed
Dpn1
NEB turbo
2O-T
High-Fidelity DNA
mutagenesis (30 cycles of 95°C
MsTOP1-839t Polymerase (Thermo
for 30 sec, 70°C for 30 sec, 72°C
Scientific)
for 4.5 min)
2O-T
Phusion Hot Start II
QuickChange site-directed
Dpn1
NEB turbo
MsTOP1-785t High-Fidelity DNA
mutagenesis (30 cycles of 95°C
Polymerase (Thermo
for 30 sec, 70°C for 30 sec, 72°C
Scientific)
for 4.5 min)
2O-T
Phusion Hot Start II
QuickChange site-directed
Dpn1
NEB turbo
MsTOP1-701t High-Fidelity DNA
mutagenesis (30 cycles of 95°C
Polymerase (Thermo
for 30 sec, 70°C for 30 sec, 72°C
Scientific)
for 4.5 min)
2O-T
Phusion Hot Start II
QuickChange site-directed
Dpn1
NEB turbo
MtTOP1-840t High-Fidelity DNA
mutagenesis (30 cycles of 95°C
Polymerase (Thermo
for 30 sec, 70°C for 30 sec, 72°C
Scientific)
for 4.5min)
2O-T
Q5 Hot Start HighQ5 site-directed mutagenesis
KLD mix
NEB 5α
MtTOP1-786t Fidelity Master Mix
(25 cycles of 95°C for 30 sec,
(New England
65°C for 30 sec, 72°C for 4.5 min)
Biolabs)
2O-T
Phusion Hot Start II
QuickChange site-directed
Dpn1
NEB turbo
MtTOP1-704t High-Fidelity DNA
mutagenesis (30 cycles of 95°C
Polymerase (Thermo
for 30 sec, 70°C for 30 sec, 72°C
Scientific)
for 4.5 min)
Table 1.3 Methods and materials used for site directed mutagenesis of mycobacterial topoisomerase I
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Protein expression and purification
Wild-type MsTOP1 and its mutant proteins were overexpressed in E. coli
BL21 star (DE3) strain (Invitrogen). Wild-type MtTOP1 and its mutant proteins
were overexpressed in E. coli T7 Express crystal strain (New England Biolabs).
The cells were grown at 30°C overnight. Overnight cell cultures diluted 1:100
were incubated in LB medium with 100 µg/ml carbenicillin at 30°C to exponential
phase (OD600=0.4). 1 mM IPTG was added to BL21 star (DE3) cell culture. 0.4
mM IPTG was added to T7 express crystal cell culture. Induced cell culture was
grown at 22°C overnight. Cell cultures were centrifuged at 4500 rpm at 4°C for
30 min. Cell pellets were resuspended in lysis buffer (50 mM sodium phosphate,
0.3 M NaCl, 10 mM imidazole, and 1 mg/ml lysozyme, pH8.0). The resuspended
cell mixture was left on ice for 1 hr. Four cycles of freeze–thawing were used to
lyse cell. The cell lysate was centrifuged at 32000 rpm at 4°C for 2 hr. The
soluble cell lysate were collected and mixed with Ni-Sepharose 6 Fast Flow
beads (GE Healthcare) at 4°C for 1 hr. The beads were packed into a column
and the AKTA purifier 100 (GE healthcare Life Sciences) was used for
purification. About 350 ml of wash buffer (50 mM sodium phosphate, 0.3 M
NaCl, 20 mM imidazole, pH 8.0) were used to wash column after sample loading.
Recombinant proteins were eluted with elution buffer (50 mM sodium phosphate,
0.3 M NaCl, 400 mM imidazole, pH 8.0). The eluted fractions were analyzed with
10% SDS-PAGE gel and eluted fractions with recombinant proteins were
dialyzed against buffer A (20 mM potassium phosphate, 1 mM EDTA pH 8.0,
10% glycerol) + 0.1 M KCl. TEV protease (tobacco etch virus protease) (Kapust
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et al., 2002) was added to the purified protein after dialysis at the ratio of 1:40
(TEV protease: purified protein). The His-tagged TEV protease was purified in
our lab. The recombinant protein with His-Mocr tag was digested at 20°C for 6 hr
followed by incubation at 4°C overnight in reaction buffer (50 mM Tris-HCl, 0.5
mM EDTA and 1 mM DTT, pH 8.0).

Ni-Sepharose 6 Fast Flow resin (GE

Healthcare Life Sciences) was used to remove cleaved N-terminal His6-Mocr tag
and His-tagged TEV protease. The recombinant proteins were eluted with wash
buffer (20 mM Tris-HCl, 0.3 mM KCl, pH 8.0) and concentrated with Ultra
Centrifugal Filters (EMD Millipore) to ~10 ml. Recombinant proteins were then
loaded

onto

size

exclusion

chromatography

column

HiPrep™ 26/60

Sephacryl® S-200 (GE Healthcare Life Sciences) to remove nuclease and
proteins co-eluted in previous steps. Recombinant proteins were eluted with
column buffer (20 mM Tris-HCl, 0.3 M KCl, pH 8.0) and dialyzed against storage
buffer (0.1 M potassium phosphate, 0.2 mM EDTA pH 8.0, 50% glycerol). The
final step is to measure the protein concentrations with the Bio-Rad Bradford
protein assay using bovine serum albumin (BSA, Bio-Rad) as standard.
Complementation of topA temperature sensitive mutation in E. coli AS17
strain
Wild-type and mutant mycobacterial topoisomerase I clones in the 2O-T
vector were electro-transformed into E. coli AS17 (F- topA17(am) pLL1(Tet
supD43,74)) strain. The AS17 transformants were grown at 30°C overnight, in
LB medium with 100 µg/ml carbenicillin. The OD600 of overnight cultures were
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checked and adjusted to OD600=1 with LB medium (100 µg/ml carbenicillin). The
adjusted cell culture was serially diluted with LB medium (100 µg/ml carbenicillin)
and 5 µl each dilution was spotted on LB agar plate with 100 µg/ml carbenicillin.
The plates in duplicates were incubated at 30°C and 42°C for 2 days.

Relaxation assay
Wild-type and mutant mycobacterial topoisomerase I proteins were serially
diluted.

Diluted proteins were incubated with 250 ng negatively supercoiled

plasmid pBAD/thio (purified by CsCl density gradient centrifugation) in the
volume of 20 µL with 10 mM Tris–HCl (pH 8.0), 100 mM NaCl, 0.1 mg/ml gelatin,
and 5 mM MgCl2 at 37°C for 30 min. The reactions were terminated by addition
of 4 µL of stop buffer (50 mM EDTA, 50% glycerol and 0.5% (v/v) bromophenol
blue). The DNA was then electrophoresed in a 1% agarose gel with TAE buffer
(40 mM Tris-acetate, pH 8.0, 2 mM EDTA). The gels were stained with 1 µg/mL
concentration ethidium bromide for 1 hr and photographed over UV light.
In the relaxation rate assay of wild-type and mutant proteins without Cterminal tail, 30 ng wild-type MtTOP1, wild-type MsTOP1, MtTOP1-910t and
MsTOP1-909t was incubated with 250 ng negatively supercoiled plasmid
pBAD/thio in 20 µl of 10 mM Tris–HCl (pH 8.0), 100 mM NaCl, 0.1 mg/ml gelatin,
and 5 mM MgCl2 at 37°C for 1, 2, 3, 6, 9, 12, 15, 30 min. The reactions were
terminated with 4 µL of stop buffer and analyzed by electrophoresis in 0.8%
agarose gel with TAE buffer.

The gels were stained with 1 µg/mL ethidium

bromide for 1 hour and photographed over UV light.
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In the relaxation assay of wild-type MsTOP1 and MsTOP1-839t, 100 ng
MsTOP1, 100 ng MsTOP1-839t and 400 ng MsTOP1-839t were incubated with
250 ng negatively supercoiled plasmid pBAD/thio in 20 µl of 10 mM Tris–HCl
(pH 8.0), 50 mM NaCl, 0.1 mg/ml gelatin, and 5 mM MgCl2 at 37°C for different
times, the reactions were terminated with 4 µl of stop buffer and analyzed by
electrophoresis in 1% agarose gel with TAE buffer. The gels were stained with 1
µg/mL concentration ethidium bromide for 1 hour and photographed over UV
light.
Electrophoretic mobility shift assay (EMSA)
The oligonucleotide substrates STS32 and MT3 (Table 1.4) were labeled
with γ-32P-ATP at the 5’ end by T4 polynucleotide kinase (New England
BioLabs).

The labeling reactions were carried out at 37°C for 30 min and

terminated at 75°C for 15min.

γ-32P labeled oligonucleotide substrates were

purified after the labeling reaction using a Sephadex G-50 spin column (STS32)
or Sephadex G-25 column (MT3) (GE Healthcare).

Purified substrates were

eluted in 10 mM Tris-HCl, pH 8.0. The electrophoretic mobility shift assay was
carried out in 10 µl of 20 mM Tris-HCl (pH8.0), 100 µg/ml BSA, 18% glycerol, 0.5
mM EDTA. In the STS32 mobility shift assay, 1-4 pmol wild-type MtTOP1 and
MsTOP1, or mutant proteins were incubated with 5 pmol STS32 at 37°C for 5
min. In the MT3 electrophoretic mobility shift assay, 1-10 pmol wild-type MtTOP1
and MsTOP1, mutant proteins MtTOP1-704t and MsTOP1-701t were incubated
with 2.5 pmol MT3 at 37°C for 5 min. The reactions were then placed on ice for 5
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min. The non-covalent protein-DNA complex and free substrate were separated
by electrophoresis in 8% polyacrylamide gel with 0.5×TBE (45 mM Tris-HCl, 45
mM Borate, 1 mM EDTA, pH 8.3) buffer at 6 V/cm for 4.5 hours. The gels were
vacuum dried at 80°C for 2 hours. The dried gel was analyzed by Phosphorlmager.

Cleavage assay
The oligonucleotide substrates in Table 1.4 were labeled with γ-32P-ATP
at the 5’ end. 1 pmol of wild-type MtTOP1 and MtTOP1-704t were incubated
with 0.5 pmol 32P-labeled oligonucleotide substrates STS32, MT2-13, MT2-14,
MT3, MT3-N13, MT3-C13 in 5 µl of 10 mM Tris–HCl (pH 8.0) at 37°C for 30 min.
Wild-type MtTOP1, wild-type MsTOP1 and mutant proteins were serially diluted
to 2 pmol/µl, 1 pmol/µl, 0.5 pmol/µl, 0.25 pmol/µl, 0.125 pmol/µl, and 0.63
pmol/µl. 0.5 pmol oligonucleotide substrates were incubated with serially diluted
proteins in 5 µl of 10 mM Tris–HCl (pH 8.0) at 37°C for 30 min. The equal
volume of loading buffer (79% formamide, 0.2 M NaOH, 0.04% bromophenol
blue) was added to terminate the cleavage reactions. All the reactions were then
heated at 95 °C for 5 min. The long oligo (STS32 and MT2) cleavage products
were electrophoresed in 15% sequencing gel. The short oligo (MT3, MT2-13 and
so on) cleavage products were electrophoresed in 20% sequencing gel. The
TBE buffer (89 mM Tris-Cl, 89 mM Borate, 2 mM EDTA pH 8.3) was used as
running buffer. Gels were analyzed by Phosphor-lmager.
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In the cleavage assay using substrate MT3 with Mg2+, the oligonucleotide
substrate MT3 was labeled with γ-32P-ATP at the 5’ end.

1 pmol wild-type

MtTOP1, MtTOP1-840t, MtTOP1-786t and MtTOP1-704t were incubated with 0.5
pmol oligonucleotide substrate MT3 in 5 µl of 10 mM Tris–HCl (pH 8.0) at 37°C
for 15 min. 1 M NaCl and 5 mM MgCl2 were added into the cleavage reaction for
15 min further incubation at 37°C. Another reaction condition is to add 2 mM
MgCl2 into the cleavage reaction for 5 min further incubation at 37 °C. The
reactions were terminated with equal volume of loading buffer (79% formamide,
0.2 M NaOH, 0.04% bromophenol blue) and heated at 95 °C for 5 min. The
reaction products were analyzed by electrophoresis in 15% sequencing gel. The
TBE buffer was used as running buffer.

Gels were analyzed by Phosphor-

lmager.

Oligo name

Oligo sequence (5’-3’)

STS32

5′-CAGTGAGCGAGCTTCCGCêTTGACATCCCAATA-3′

MT2

5’-CAGTGAGCGAGCTTCCGCêTTGACTT-3’

MT2-14

5’-CTTCCGCêTTGACTT-3’

MTS2-13

5’-TTCCGCêTTGACTT-3’

MT3

5’-CTTCCGCêTTGACAT-3’

MT3-C13

5’-TTCCGCêTTGACAT-3’

MT3-N13

5’-CTTCCGCêTTGACA-3’

Table 1.4 Oligos used in cleavage assay. Arrows indicate the cleavage site.
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Religation assay
The oligonucleotide substrate STS32 were labeled with γ-32P-ATP at the
5’ end.

In the religation assay, 1 pmol wild-type and mutant proteins were

incubated with 0.5 pmol oligonucleotide substrate STS32 in 5 µl of 10 mM Tris–
HCl (pH 8.0) at 37°C for 15 min. 1 M NaCl, 5 mM or 10 mM MgCl2 were added
into the cleavage reaction respectively for 15 min further incubation at 37°C. The
reactions were terminated with equal volume of loading buffer (79% formamide,
0.2 M NaOH, 0.04% bromophenol blue) and heated at 95°C for 5 min. The
reaction products were analyzed by electrophoresis in 15% sequencing gel. The
TBE buffer was used as running buffer.

Gels were analyzed by Phosphor-

lmager.
Catenation assay
Catenation of M13mp18 ssDNA circles was assayed with a protocol
similar to previously described conditions (Bhaduri et al., 1998).

Wild-type

MsTOP1, Wild-type MtTOP1, MtTOP1-704t was diluted into 0.5 pmol/µl, 0.25
pmol/µl, 0.125 pmol/µl. The reaction volume of 20 µl contained 20 mM Tris–HCl
(pH 8.0), 20 mM KCl, 2 mM MgCl2, 0.05 mg/ml BSA, 10 mM spermidine, 30%
glycerol, and 0.5 µg of M13mp18 ssDNA (from Bayou Biolabs). After incubation
with the indicated amount of topoisomerase protein for 1 hr at 52°C, the reactions
were terminated with the addition of 1% SDS, 5 mM EDTA, and 12 µg of
proteinase K (New England Biolabs) and were left at 37°C for 1 hr before
electrophoresis in 0.8% agarose gel.

The TAE buffer was used as running
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buffer. The gels were stained with 1 µg/mL concentration ethidium bromide for 1
hr and photographed over UV light.
Decatenation assay
Decatenation of kinetoplast DNA (kDNA) was carried out in the reaction
volume of 20 µl containing 50 mM Tris–HCl (pH 8.0), 120 mM KCl, 10 mM MgCl2,
30 mg/ml BSA, 0.5 mM DTT, 30% glycerol, and 150 ng kDNA (from Topogen).
MtTOP1 and MtTOP1-704t was diluted to 6 pmol/µl, 3 pmol/µl and 1.5 pmol/µl. 1
µl diluted topoisomerase protein was added to decatenation reaction and
incubated at 45°C for 1 h. To test the stability of kDNA in 45°C, kDNA was
incubated without enzyme at 45°C for 1 hr. The human topoisomerase IIα was
used as the positive control for decatenaton activity, The human TOPIIα
decatenation reaction was carried in 50 mM Tris–HCl (pH 8.0), 120 mM KCl, 10
mM MgCl2, 3 mM ATP, 30 mg/ml BSA, 0.5 mM DTT, 30% glycerol, and 150 ng
kDNA (from Topogen). Reactions were terminated with the addition of 4 µl of 5%
sarkosyl, 0.025% bromophenol and 50% glycerol before electrophoresis in 1%
agarose gel. TAE buffer containing 0.5 µg/ml ethidium bromide was used as
running buffer. The gels photographed over UV light.
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RESULTS
Complementation of topA temperature sensitive mutation in E. coli AS17 by
recombinant mycobacterial topoisomerase I
Previous studies showed that E. coli AS17 with the temperature sensitive
mutation in topoisomerase I gene (topAts) complemented by recombinant
MtTOP1 could grow at the non-permissive temperatures of 37°C and 42°C
(Narula et al., 2010). In the current study, plasmids with mutant MtTOP1 and
MsTOP1 genes in the 2O-T vector were transformed into E. coli AS17 strain.
Escherichia coli AS17 strain complemented with 2O-T vector was used as a
negative control. Escherichia coli AS17 strain complemented with plasmids 2OTMtTOP1 and 2OT-MsTOP1 were used as positive control. As the results showed
in Figure 1.3, E. coli AS17 with vector could not grow at 42°C.

Wild-type

MtTOP1 and MsTOP1 complemented the topAts mutation in the chromosome of
E. coli AS17 and they are sufficient for the growth of E. coli AS17. Strains
transformed with mutant plasmids, AS17/2OT MtTOP1-910t, AS17/2OT
MtTOP1-840t, AS17/2OT MsTOP1-909t, and AS17/2OT MsTOP1-839t also grew
at 42°C.

Mutant strains AS17/2OT MtTOP1-786t, AS17/2OT MtTOP1-704t,

AS17/2OT MsTOP1-839t, and AS17/2OT MsTOP1-701t had no growth or little
growth at 42°C.

These data showed that NTD combined with C-terminal

subdomains D5 and D6 could not support the growth of E. coli. The addition of
subdomain D7 is minimally require for in vivo viability.
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Figure 1.3 Growth of E. coli AS17 complemented by recombinant mycobacterial
topoisomerase I at 30°C and 42°C in LB agar plates.
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Relaxation assay of mycobacterial topoisomerase I with negatively
supercoiled DNA
Previous studies showed that MsTOP1 with only NTD (D1-D4) or CTD
(D5-D8+basic tail) lost the relaxation activity (Jain and Nagaraja, 2006). The
truncated proteins of mycobacterial topoisomerase I that retained individual
subdomains of the CTD may maintain partial relaxation activity. In the agarose
gel electrophoresis results, 100 ng wild-type MsTOP1 and wild-type MtTOP1 fully
relaxed the 250 ng negatively supercoiled DNA substrate (Figure 1.4, Figure
1.5). In contrast, 200 ng truncated enzyme MsTOP1-701t and MtTOP1-704t that
retained D1-D5 did not show any relaxation activity (Figure 1.4A, Figure1.5A). In
Figure 1.4B and Figure 1.5B, 100 ng truncated enzyme MsTOP1-785t and
MsTOP1 786t with D1-D6 did not show any difference from negative control. In
Figure 1.4C and Figure 1.5C, 200 ng MsTOP1-839t and MtTOP1-840t showed
partial weak relaxation activity.

Compared to the wild-type mycobacterial

topoisomerase I, the relaxation activity of MtTOP1-840t and MsTOP1-839t was
reduced about 16-fold.

Mutant proteins MtTOP1-910t and MsTOP1-909t are

more active than other truncated enzymes in relaxation assays (Figure 1.4D,
Figure1.5D). Compared with products from each reaction of wild-type MtTOP1
and MsTOP1, the relaxation activity of MtTOP1-910t and MsTOP1-909t
decreased 2- to 4-fold. This data shows that truncation mutants with C-terminal
subdomains D1-D7 retain partial relaxation activity, and it is sufficient for
supporting the viability of E. coli in vivo when present in high copy number
plasmid 2O-T. Subdomain D5 and D6 subdomains combined with NTD could not
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maintain the relaxation activity of mycobacterial topoisomerase I. Subdomain D7
needs to be present for the relaxation of negatively supercoiled DNA. Serial
dilutions of MtTOP1-910t and MsTOP1-909t showed that the truncated mutations
with D1-D8 that were miss the basic tail at the C-terminus had a slight reduction
in relaxation activity when compared to wild-type.
Mutant proteins MtTOP1-909t and MsTOP1-910t were incubated with 250
ng negatively supercoiled DNA for 1, 2, 3, 6, 9, 15, 30, 15 and 60 min and
compared with 30 ng wild-type MtTOP1 and MsTOP1 incubated at the same
conditions and times (Figure 1.6). At each time point, wild-type MtTOP1 and
MsTOP1 are more active than MtTOP1-910t and MsTOP1-909t. Mutant proteins
MtTOP1-910t and MsTOP1-909t have reduced relaxation catalytic rate. The final
products are more fully relaxed for the wild-type enzymes. The C-terminal tail
that is absent in MtTOP1-910t and MsTOP1-909t enhanced the relaxation
activity and processivity of mycobacterial topoisomerase I.
Removed of negative supercoils by 30 ng of wild-type and mutant
mycobacterial topoisomerase I began slow starting from 9-15 min, as the partially
relaxed DNA has less single-stranded DNA region for binding to the enzyme. In
Figure 1.7, 100 and 400 ng MsTOP1-839t was incubated with 250 ng negatively
supercoiled DNA at 37°C up to 180 min. MsTOP1-839t exhibited only partial
relaxation activity even at 180 min and a slow catalytic rate. This result showed
that while the presence of D5-D7 can allow relaxation of negatively supercoiled
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DNA by mycobacterial topoisomerase I, subdomain D8 played an important role
in the catalysis of the relaxation reaction.

Figure 1.4 Relaxation assays of serially diluted wild-type and mutant MsTOP1 with
negatively supercoiled pBAD/Thio DNA. (A) Relaxation assay of wild-type MsTOP1
and MsTOP1-701t. (B) Relaxation assay of wild-type MsTOP1 and MsTOP1-785t. (C)
Relaxation assay of wild-type MsTOP1 and MsTOP1-839t. (D) Relaxation assay of wildtype MsTOP1 with MsTOP1-909t. No, no enzyme added.
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Figure 1.5 Relaxation assays of serially diluted wild-type and mutant
MtTOP1 with negatively supercoiled pBAD/Thio DNA. (A) Relaxation assay
of wild-type MtTOP1 with MtTOP1-704t. (B) Relaxation assay of wild-type
MtTOP1 and MtTOP1-786t. (C) Relaxation assay of wild-type MtTOP1 and
MtTOP1-840t. (D) Relaxation assay of wild-type MtTOP1 and MtTOP1-910t.
No, no enzyme added.
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Figure 1.6 Relaxation time course for mycobacterial topoisomerase I with
negatively supercoiled pBAD/Thio DNA. (A) Assays of 30 ng wild-type MtTOP1 and
MtTOP1-910t. (B) Assays of 30 ng wild-type MsTOP1 and 30 ng MsTOP1-909t. No, no
enzyme added.
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Figure 1.7 Relaxation time course for wild-type MsTOP1 and MsTOP1-839t with
negatively supercoiled pBAD/Thio DNA. (A) 100 ng MsTOP1 and 100 ng MsTOP1839t were incubated at 37°C for different times (5-60 min). (B) 400 ng MsTOP1 was
incubated at 37°C for different times for 30, 60, 120, 150, 180 min.
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Mycobacterial topoisomerase I truncated mutant proteins with C-terminal
subdomain D5 only have reduced binding to oligonucleotide STS32 and
MT3
In an earlier study, the NTD and CTD of mycobacterial topoisomerase I
were found to each bind to DNA (Jain and Nagaraja, 2006). In this study, the
EMSA of oligonucleotide STS32 and MT3 were used to study the DNA binding
activity of wild-type and mutant mycobacterial topoisomerase (Figure 1.8, Figure
1.9).

In the DNA binding assay of STS32, MtTOP1-786t, MtTOP1-704t,

MsTOP1-785t and MsTOP1-701t showed less binding activity than wild-type and
other mutant mycobacterial topoisomerase I (Figure 1.8).

Deletion mutation

proteins MsTOP1-701t and MtTOP1-704t that with NTD and C-terminal
subdomain D5 have significantly reduced DNA binding activity when compared to
wild-type mycobacterial topoisomerase I with oligonucleotide STS32. Wild-type
MtTOP1 and MsTOP1 also have significantly higher binding activity than
MtTOP1-704t and MsTOP1-701t with oligonucleotide MT3 (Figure 1.9). These
results show that truncated mutant proteins with NTD and C-terminal subdomain
D5 only have significantly reduced binding to short ssDNA when compared to
wild-type mycobacterial topoisomerase I.

The C-terminal subdomains likely

contribute significantly to binding of one of the unwound DNA strand during
relaxation of negatively supercoiled DNA by mycobacterial topoisomerase I.
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Figure 1.8 Electrophoretic mobility shift assay for formation of non-covalent
complex between labeled STS32 oligonucleotide and mycobacterial
topoisomerase I. (A) EMSA assay of wild-type MtTOP1 and truncate mutant MtTOP1.
(B) EMSA assay of wild-type MsTOP1 and truncate mutant MsTOP1.
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Figure 1.9 Electrophoretic mobility shift assay of MtTOP1, MtTOP1-704t, MsTOP1 and MsTOP1-701t with
labeled MT3 oligonucleotide.
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Cleavage activity of mycobacterial topoisomerase I with 32 nucleotide long
STS32 and 25 nucleotide long MT2 substrate
We used serially diluted protein to test the cleavage activity of wild-type
and mutant mycobacterial topoisomerase I with 5’-labeled oligonucleotide STS32
and MT2. Oligonucleotide STS32 contains 32 nucleotides, and MT2 contains 25
nucleotides.

The results of wild-type MtTOP1, MtTOP1-910t, MtTOP1-840t,

MtTOP1-786t and MtTOP1-704t cleavage activity assay with STS32 substrate
show that all the truncated mutant M. tuberculosis topoisomerase I can cleave
this substrate (Figure 1.10). The cleavage activity assay results of wild-type
MsTOP1, MsTOP1-909t, MsTOP1-839t, MsTOP1-785t and MsTOP1-701t with
oligonucleotide STS32 also show that all the truncated mutant M. smegmatis
topoisomerase I have cleavage activity with oligonucleotide STS32 (Figure 1.11).
The cleavage activity results in Figure 1.12 show that wild-type MsTOP1,
MsTOP1-909t, MsTOP1-839t, MsTOP1-785t and MsTOP1-701t performed DNA
cleavage on substrate MT2. Figure 1.13 showed that MtTOP1-704t formed a
higher level of cleavage product than wild-type MtTOP1 with MT2 substrate.
Similar results were observed between MsTOP1 and MsTOP1-701t (Figure
1.12).

The deletion of C-terminal subdomains D6-D8 of mycobacterial

topoisomerase I did not lead to the loss of the cleavage activity. A previous
study has concluded that the NTD of MsTOP1 forming at residues 616 can
cleave DNA (Jain and Nagaraja, 2006). These studies show that active site of
mycobacterial topoisomerase I in the NTD can carry out DNA cleavage in the
absence of most of the CTD.

The results in Figure 1.13 suggest that
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subdomains D6-D8 may compete with the active site in NTD for binding to the 25
nucleotides long MT2 substrate, so that more cleavage product is formed from
the NTD+D5 form of mycobacterial topoisomerase I with the rest of the CTD not
present. As protein/oligonucleotide ratio increases, more cleavage product is
formed from MtTOP1-704t, while cleavage by wild-type becomes suppressed
because the CTD subdomains may have higher affinity for the MT2 substrate
than the NTD active site.

The longer length STS substrate may be able to

interact simultaneously with both the NTD and CTD. This is further investigated
with shorter oligonucleotide substrates.
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Figure 1.10 Cleavage activity assay wild-type MtTOP1, MtTOP1-910t, MtTOP1-840t, MtTOP1-786t and MtTOP1704t with STS32 substrate.
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Figure 1.11 Cleavage activity assay of wild-type MsTOP1, MsTOP1-909t, MsTOP1-839t, MsTOP1-785t and
MsTOP1-701t with STS32 substrate.

61

Figure 1.12 Cleavage activity assay of wild-type MsTOP1, MsTOP1-909t, MsTOP1-839t, MsTOP1-785t and
MsTOP1-701t with MT2 substrate.
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Figure 1.13 Cleavage of MT2 substrate by MtTOP1-704t is more robust than wildtype MtTOP1. (A) Assay of MT2 substrate cleavage by serially diluted MtTOP1-704t
and MtTOP1 cleavage assay with MT2. (B) Analysis of percentage cleavage product
analysis. The average deviation from two experiments is shown.

Cleavage assay of mycobacterial topoisomerase I with short
oligonucleotides
Short oligonucleotides (Figure 1.14) MT2-14, MT2-13, MT3-N13 and MT3
contain 13-14 nucleotides. wild-type MtTOP1 at 1 pmol cleavage assay reaction
did not show any cleavage activity with these short oligos.

However, high

cleavage activity was observed with 1 pmol MtTOP1-704t and these short oligos.
Oligonucleotide MT3 (14 nucleotides) is shorter than the 32-nucleotide-long
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STS32 and 25-nucleotide-long MT2. When MT3 was titrated with 0.25-2 pmol of
MtTOP1 and MsTOP1, cleavage activity of substrate MT3 (0.5 pmol) was not
observed. However, MtTOP1 and MsTOP1 at lower stoichiometry (0.063 and
0.125 pmol) produced cleavage product from MT3 (Figure 1.15, Figure 1.16). In
contrast mutant proteins with deletions in CTD produced cleavage product from
MT3 at both high and low stoichiometry of enzymes (Figure 1.15, Figure 1.16).
The DNA binding assay (Figure 1.9) showed that MsTOP1 and MtTOP1
bind MT3 at higher protein: DNA stoichiometry even when DNA cleavage was
not observed (Figure 1.15). These data suggest that the short oligonucleotide
MT3 has higher affinity for the CTD than the NTD. When the CTD of
mycobacterial

topoisomerase

I

was

fully

occupied,

additional

short

oligonucleotide will then bind to the NTD active site for DNA cleavage to occur.
This result shows that the CTD in mycobacterial topoisomerase I is responsible
for recognition of negatively supercoiled duplex DNA by interacting with one
strand of the unwound DNA and directing the complementary strand to the NTD
active site for DNA cleavage.
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Figure 1.14, Cleavage of short 13-14 base long oligo by MtTOP1-704t but not wild-type MtTOP1. Wild-type
MtTOP1 and MtTOP1-704t were incubated with STS32, MT2-14, MTS2-13, MT3, MT3-N13, MT3-C13 at 37°C for 30
min.
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Figure 1.15 Cleavage activity assay of wild-type MsTOP1, MsTOP1-909t, MsTOP1-839t, MsTOP1-785t and
MsTOP1-701t with MT3 oligonucleotide substrate.
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Figure 1.16 Cleavage activity assay of wild-type MtTOP1, MtTOP1-840t, MtTOP1-786t and MtTOP1-704t with
MT3 oligonucleotide substrate.
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Cleavage oligonucleotide MT3 in the presence of Mg (II)
It is observed that 1 pmol wild-type MtTOP1 was not able to cleave short
oligonucleotides in 10 mM Tris-HCl at 37°C. However, in the cleavage activity
assay at the presence of 2 mM Mg2+ at 37°C, 1 pmol wild-type MtTOP1 is
observed to cleave the short oligonucleotide MT3 (Figure 1.17). In the cleavage
reaction with Mg2+, MtTOP1-840t also displayed higher cleavage activity for MT3
than reaction without Mg2+. Mutant protein MtTOP1-786t did not show difference
of cleavage activity with or without Mg2+.

However, the cleavage product of

MtTOP1-704t was decreased in the presence of Mg2+ likely because DNA
religation is favored in this reaction. In the reactions with Mg2+ and 1 M NaCl
added following DNA cleavage, DNA religation takes place followed by
dissociation of the enzyme from the religated substrate. MtTOP1-704t with D5
subdomain exhibits cleavage activity without Mg2+, but religation activity with
Mg2+ for short oligo.

It is hypothesized that although the CTD subdomains D6-

D8 have high binding affinity for short oligo, NaCl and Mg2+ dissociate the short
oligos from topoisomerase CTD and allow short oligos to bind to active site for
cleavage.
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A

B

Figure 1.17 Cleavage of short oligonucleotide MT3 in the presence of Mg (II). (A)
Cleavage assay of wild-type and mutant M. tuberculosis topoisomerase I with 5 mM
Mg2+ and 1M NaCl. (B) Cleavage assay of wild-type and mutant M. tuberculosis
topoisomerase I with 2mM Mg2+.
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Religaton assay of mycobacterial topoisomerase I with oligonucleotide
STS32
The effect of C-terminal subdomains of mycobacterial topoisomerase I on
religation activity of the longer oligonucleotide substrate STS32 was also
investigated. Wild-type and mutant mycobacterial topoisomerase I all have
religation activity to convert the STS32 cleavage product back to the substrate
when Mg2+ is added to the cleavage reaction. Wild-type MtTOP1 and MtTOP1910t showed less efficient religation activity than MtTOP1-840t, MtTOP1-786t
and MtTOP1-704t (Figure 1.18, Table 1.5). Wild-type MsTOP1 and its mutant
proteins showed similar results as MtTOP1 and its mutant proteins. Because the
active site is in the NTD of mycobacterial topoisomerase I, the mutants with
deletion of the CTD in mycobacterial topoisomerase I can retain religation
activity. The DNA binding function of CTD may influence the DNA interaction at
the active site in NTD or the enzyme conformational change required for bringing
the ends of the cleaved DNA back together, so MtTOP1, MsTOP1, MtTOP1-910t
and MsTOP1-909t showed less efficient religation activity.

Relaxation of

negatively supercoiled DNA requires passage of the complementary DNA strand
through the break of the strand cleaved at the active site.

The strand passage

has to take place prior to religation of the DNA break at the active site.

We

hypothesize that C-terminal subdomain D8 and C-terminal tail are involved in
binding and passage of a strand of the unwound duplex DNA during relaxation of
negatively supercoiled DNA by mycobacterial topoisomerase I.
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Figure 1.18 Comparison of religation activity of wild-type and mutant
mycobacterial topoisomerase I with oligonucleotide STS32 substrate.
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A
WT MsTOP1

MsTOP1-909t

MsTOP1-839t

MsTOP1-785t

MsTOP1-701t

Mg2+(mM)

0

5

10

0

5

10

0

5

10

0

5

10

0

5

10

Cleavage
product
level

0.07

0.03

0.03

0.10

0.05

0.03

0.11

0.01

0.01

0.12

-

-

0.17

-

-

B
WT MtTOP1
Mg2+(mM)

0

Cleavage
0.07
product level

MtTOP1-910t

MtTOP1-841t

MtTOP1-786t

MtTOP1-704t

5

10

0

5

10

0

5

10

0

5

10

0

5

10

0.02

0.01

0.2

0.03

0.02

0.35

-

-

0.35

-

-

0.37

-

-

Table 1.5 Product analysis of religation activity of wild-type and mutant mycobacterial topoisomerase I with
oligonucleotide STS32 substrate. (A), Product analysis of Wild-type and mutant MsTOP1. (B), Product analysis of
wild-type and mutant MtTOP1. The cleavage product was calculated by Cleavage product/total oligo substrate.
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Catenation assay and decatenation assay
There are two types of IA family topoisomerases, topoisomerase I and
topoisomerase III in most species of bacteria that have been studied. Single
molecule studies have shown that E. coli topoisomerase III (EcTOP III) is much
more efficient than EcTOP I in DNA catenation/decatenation, while EcTOP I can
remove negative supercoils much more rapidly (Terekhova et al., 2013, 2014).
Since M. tuberculosis and other mycobacteria only have one type of IA
topoisomerase enzyme, MtTOP1 is likely to be required for the resolution of
ssDNA recombination and replication intermediates. The catenation activity of
MsTOP1 has been demonstrated previously with M13 ssDNA since MtTOP1704t was found to have robust DNA cleavage–religation capabilities, the
truncated enzyme was assayed for catenation of single-stranded M13mp18 DNA
circles to determine if it can catalyze passage of a ssDNA through the break
created by enzyme cleavage on another ssDNA circle. The results (Figure 1.19)
showed that MtTOP1-704t has comparable catenation activity to that of fulllength MtTOP1 and MsTOP1. The catenated DNA network in kDNA is stable at
45°C without topoisomerase treatment (Figure 1.20). Human topoisomerase II
can decatenate kDNA to generate the monomeric DNA. This monomeric DNA
includes nicked open circular DNA and closed circular relaxed DNA. Wild-type
MtTOP1 has the ability to decatenate kDNA into nicked, open circular DNA, but
is not able to release decatenated closed circular relaxed DNA because cutting
of a double-strand of DNA is required.

These results indicated that

mycobacterial

able

topoisomerase

I

should

73

be

to

resolve

topological

intermediates in replication and recombination that need passing a single-strand
of DNA across another single-stranded DNA. Deletion protein MtTOP1-704t has
comparable decatenation activity when compared to that of full-length MtTOP1.
The CTD is not required for this activity.

Figure 1.19 Catenation of single-stranded M13mp18DNA by MsTOP1, MtTOP1 and
MtTOP1-704t. Single-stranded M13mp18 DNA was incubated with the indicated
amount of MtTOP1 or MtTOP1-704t before proteinase K treatment. C: circular ssDNA; L:
linear ssDNA; CC: catenated circular ssDNA.

Figure 1.20 Decatenation of kDNA network by MtTOP1 and MtTOP1 704t. Lane 1,
negative control, no enzyme; Lane 2, positive control, human topoisomerase IIα.
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DISCUSSION
Mutant enzyme MtTOP1-704t maintains cleavage, religation, catenation
and decatenation activities.

One reason is that the active site tyrosine of

mycobacterial topoisomerase I is in the NTD. Deletion of C-terminal subdomain
D6, D7, D8 and the C-terminal tail does not affect those activities at active site
and events at the catalytic regions in the NTD. Escherichia coli AS17 with topAts
mutation cannot be complemented by MtTOP1-704t or MtTOP1-786t strains at
42°C (Figure 1.3) because MtTOP1-704t and MtTOP1-786t lacked the relaxation
activity required during the cellular process of E. coli AS17. Partial relaxation
activities of MtTOP1-840t, MtTOP1-910t, MsTOP1-839t and MsTOP1-909t
enable growth of E. coli AS17 complemented strains at 42°C. Proteins with
NTD+D5+D6+D7 domains that were expressed from a high copy number
plasmid are sufficient to solve the genomic topological barriers and support the
growth of E. coli AS17.
In the DNA binding assay with long oligo STS32 and short oligo MT3, wildtype MsTOP1 and MtTOP1 displayed higher binding activity than mutant enzyme
MsTOP1-701t and MtTOP1-704t.

These results demonstrate that CTD for

mycobacterial topoisomerase I contribute significantly to ssDNA binding. The
CTD DNA binding site of mycobacterial topoisomerase I can bind ssDNA with
higher affinity than the NTD. The results from the cleavage activity assay of MT3
with short 14-nucleotide-substrate with and without Mg2+ indicated that before the
active site is occupied, ssDNA binds to CTD first. This could explain why for
wild-type topoisomerase I cleavage of long oligonucleotides STS32 and MT2
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produces less cleavage products form from 2 pmol and 1 pmol MsTOP1 and
MtTOP1 than 0.5 pmol of enzyme. Since CTD of mycobacterial topoisomerase I
has high affinity for ssDNA, higher amount of enzyme binds more ssDNA in its
CTD. The increased enzyme: DNA ratio reduces the DNA binding at NTD for
cleavage by the wild-type mycobacterial topoisomerase I.

Therefore less

cleavage product was produced when wild-type mycobacterial topoisomerase I is
in excess. MtTOP1-704t and MsTOP1-701t exhibit higher cleavage activity than
wild-type mycobacterial topoisomerase I with MT2 (Figure 1.12, Figure 1.13),
because they do not have the CTD subdomains to compete with the NTD active
site for DNA binding. It can be postulated that high CTD binding affinity prevents
the interaction between N-terminal domain of wild-type topoisomerase I with
DNA, unless both strands of unwound duplex DNA are available in negatively
supercoiled DNA.
In the religation activity assays, NaCl serves to dissociate oligos from DNA
topoisomerases following religation. A previous study showed that Mg2+ is not
required for DNA cleavage by wild-type MsTOP1, but Mg2+ is needed for
religation (Bhat et al., 2009).

In our cleavage assay of mycobacterial

topoisomerase I with MT3 substrate wild-type MtTOP1 and each mutant enzyme
responded differently to the presence of Mg2+. It indicates that Mg2+ may interact
with the four C-terminal subdomains to affect DNA binding there. The change in
CTD-DNA interaction may affect the DNA cleavage-religation at the NTD active
site in turn. This may be a direction for future study to understand the role of the
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mycobacterial topoisomerase I CTD in the conformational change of the enzymeDNA complex that accompanies the relaxation of supercoiled DNA.
In the cleavage assay of MsTOP1-909t with MT3, the cleavage activity of
MsTOP1-909t did not show the clear response to different amounts of enzyme
being added. Besides, in the cleavage activity assay of MsTOP1-909t and
MtTOP1-910t with STS32 substrate, 1 pmol and 2 pmol reactions of these two
enzymes did not show less cleavage product than 0.5 pmol reactions.

This

suggests that the C-terminal positively charged tail has a role for ssDNA binding
in mycobacterial topoisomerase I.

MsTOP1-909t had decreased relaxation

activity without the C-terminal tail.

The sequence of wild-type MsTOP1’s C-

terminal tail is “RGPVKKKAPAKKAAKKAPAKKAAAKKA”. It contains 5 lysine
repeats. A recent study indicated that the C-terminal lysine repeats found in
bacterial DNA topoisomerase I stabilize the enzyme-DNA complex (Strzalka et
al., 2017). Without the C-terminal positively charged tail to stabilize the enzymeDNA complex, the CTD may lose some of the DNA binding affinity.
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CHAPTER 2: TYPE IA TOPOISOMERASE MECHANISM-ACTIVE SITE
STRUCTURE AND INTERACTIONS
ABSTRACT
Type IA topoisomerases are present in all organisms for multiple vital
cellular processes that include maintaining optimal DNA supercoiling density, and
resolution of recombination or replication intermediate. Their conserved catalytic
domains form an active site that can cleave and rejoin a single DNA strand.
Mg2+ is required for catalysis but not for DNA cleavage. We have obtained new
structures of Mycobacterium tuberculosis topoisomerase I (MtTOP1).

Crystal

structure of MtTOP1-704t (amino acids A2-T704) was obtained. Structures with
ssDNA substrate bound to the active site with and without Mg2+ ion present were
also investigated. Significant enzyme conformational changes upon DNA binding
place the catalytic tyrosine in a pre-transition position for cleavage of a specific
phosphodiester linkage to form a covalent intermediate.

Meanwhile, the

enzyme/DNA complex with Mg2+ bound at the active site may present the posttransition state for religation in the enzyme’s multiple-state DNA relaxation
activity. The first observation a divalent metal ion coordinated with the TOPRIM
residues in the active site of a type IA topoisomerase allows assignment of likely
catalytic role for the individual divalent ion and draws a comparison to proposed
mechanism for type IIA topoisomerases.

The critical function of a strictly

conserved glutamic acid in acid-base catalysis of the DNA cleavage step was
clearly demonstrated by site-directed mutagenesis. The functions assigned to
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the Mg2+ ion can account for the requirement of metal ions for DNA rejoining but
not DNA cleavage by type IA topoisomerases. This work provides new functional
insights into the more stringent requirement for DNA rejoining versus cleavage by
type IA topoisomerase and further establishes the potential for select interference
of DNA rejoining by this validated TB drug target.

INTRODUCTION
Mycobacterium tuberculosis is the chief causative agent of tuberculosis,
the leading cause of morbidity and mortality globally with an estimated 10.4
million cases and 1.8 million deaths annually as reported by WHO this year. M.
tuberculosis topoisomerase I (MtTOP1) is a validated target for much needed
new antibiotics that can be used against the MDR-TB cases that are difficult to
treat (Ahmed et al., 2014; Nagaraja et al., 2017; Ravishankar et al., 2015).
Topoisomerases control the topological state of the genome, thus affecting vital
cellular processes including replication, transcription, recombination and repair
(Chen et al., 2013; Wang, 2002).

Type I topoisomerases catalyze DNA

topological transformations by breaking and rejoining a single-strand of DNA at a
time, and are divided into type IA and type IB subfamilies based on distinctively
different protein sequences and catalytic mechanisms (Baker et al., 2008;
Corbett and Berger, 2004; Vos et al., 2011).

MtTOP1 and topoisomerase I

present in all bacterial pathogens are type IA topoisomerases that are needed for
resolving topological barriers that require the passage of DNA through the break
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created on single-stranded DNA (ssDNA)(Forterre and Gadelle, 2009). This can
be exploited for bactericidal action with topoisomerase poison inhibitors that can
stabilize the break by inhibiting DNA rejoining (Tse-Dinh, 2015). The bacterial
type IIA topoisomerases have been targeted extensively for discovery of
antibiotics that include the widely used fluoroquinolones (Aldred et al., 2014;
Tomasic and Masic, 2014). The efforts to discover bacterial topoisomerase I
inhibitors would be aided greatly by the knowledge of how DNA religation
following the formation of the covalent intermediate can be inhibited.
Type IA topoisomerases share certain functional and structural elements of
similarities with type IIA topoisomerases (Berger et al., 1998), even though these
two classes of topoisomerases appear to have evolved independently as
essential topoisomerase activities in living organisms (Forterre and Gadelle,
2009). Both type IA and type IIA topoisomerases form a 5’-phosphoryl tyrosine
linkage with cleaved DNA in a covalent intermediate (Tse et al., 1980), and
divalent metal ions are absolutely required for the change in topology catalyzed
by these topoisomerases.

However, there is a significant difference in the

biochemical mechanism of these two classes of topoisomerases.

Type IA

topoisomerases can cleave DNA in the absence of divalent metal ions to form a
covalent intermediate (Depew et al., 1978), while DNA cleavage by type IIA
topoisomerases requires the addition of divalent metal ions (Sissi and Palumbo,
2009).

The requirement of metal ions for DNA religation, but not for DNA

cleavage by bacterial topoisomerase I may present an opportunity for selective
inhibition of DNA religation by small molecule inhibitors. None of the previously
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determined structures of type IA topoisomerases have divalent metal ions and
DNA both present at the active site.

The role of metal ions in the catalytic

mechanism of bacterial topoisomerase I needs to be clarified further by structural
information.
In a recent study, the structure of full-length EcTOP I in complex with
single-stranded DNA was observed (Tan et al., 2015) (PDB ID: 4RUL). The Cterminal region of EcTOP I comprises three 4-Cys zinc ribbon motifs and two zinc
ribbon-like subdomains, and a modular ssDNA-binding mode was reported. This
suggests that the C-terminal region of MtTOP1 may also contain multiple
subdomains with repeated and conserved sequence motifs even though the
sequences of EcTOP I and MtTOP1 C-terminal regions are very different with
essentially no homologies. We analyzed the structural aspects of the C-terminal
region of mycobacterial topoisomerase I.

The structure organization and

functional characterizations of subdomains in mycobacterial topoisomerase I
CTD are described in Chapter 1. In collaboration with Dr. Kemin Tan at Argonne
National Laboratory, we first determined the crystal structure of MtTOP1-704t
with the NTDs (D1–D4) and the CTD D5 (amino acids A2–T704). Collaboration
with Dr. Tan also produced additional new structures of M. tuberculosis
topoisomerase I.

For the first time, divalent metal ion can be observed to

coordinate DNA, water molecules and the acidic functional groups in the active
site of a type IA topoisomerase. We observed metal ion interactions with the
aspartates in the DxD motif (D111 and D113), proposed previously based on
genetic and biochemical data. The invariant glutamic acid (E24) in the TOPRIM
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domain is in a position for key roles in the catalysis of DNA cleavage-religation.
The requirement of the carboxyl group on E24 for acid-base catalysis of DNA
cleavage in the absence of divalent metal ions is further clarified by the study of
the E24A and E24Q mutants. Based on the new structural results, we compare
the active site of topoisomerase IA, IIA, and III; and draw their possible
similarities and differences in their catalytic mechanisms, particularly between
topoisomerase IA.

MATERIALS AND METHODS
Cloning, expression and purification
The cloning, expression and purification methods of MtTOP1-704t have
been described in Chapter 1. QuickChange site-directed mutagenesis protocol
and Phusion Hot Start II High-Fidelity DNA Polymerase (Thermo Scientific) were
used to construct mutant clones (30 cycles of 95°C for 30 sec, 70°C for 30 sec,
72°C for 4.5 min). Plasmids 2O-T MtTOP1 and 2O-T MsTOP1 were used as
templates. The primers for the PCR amplification are listed in table 2.1.

After

PCR reaction, the PCR products were purified by electrophoresis in 1% agarose
gel with TAE buffer. The template plasmids were digested by treating with Dpn1
restriction enzyme (New England Biolabs). NEB turbo competent cells (New
England Biolabs) were used for the transformation of mutant plasmids.

The

transformants were plated on the LB + 100 µg/ml carbenicillin + 2% glucose
plates. Plasmids were purified by GeneJET Plasmid Miniprep Kit (Thermo
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Scientific). Nucleotide sequencing (Eurofins genomics) was used to verify the
complete coding region of plasmids.
After verifying the sequence of mutant plasmids, mutant clones of
MsTOP1 were overexpressed in E. coli BL21 star (DE3) strain (Invitrogen).
Mutant clones of MtTOP1 were overexpressed in E. coli T7 Express crystal strain
(New England Biolabs). Cells were grown at 37°C overnight. Overnight cell
cultures were diluted 1:100 and incubated in LB medium with 100 µg/ml
carbenicillin at 30°C to exponential phase (OD600=0.4). BL21 star (DE3) cell
culture was induced by 1 mM IPTG. T7 express crystal cell culture was induced
by 0.4 mM IPTG.

Induced cell culture was grown at 22°C overnight.

cultures were centrifuged at 4500 rpm at 4°C for 30 min.

Cell

Cell pellets were

suspended in lysis buffer (50 mM sodium phosphate, 0.3 M NaCl, 10 mM
imidazole, and 1 mg/ml lysozyme, pH 8.0). The resuspended cell lysate were left
on ice for 1 hr. Four cycles of freeze-thawing were used to lyse cells. The cell
lysate was centrifuge at 32000 rpm at 4°C for 2 hr.

Mutant proteins, MtTOP1-

E24A, MtTOP1-E24Q, MsTOP1-E21A and MsTOP1-E21Q, were purified by NiSepharose 6 Fast Flow chromatography from soluble cell lysate. The protein
fractions were dialyzed against storage buffer (0.1 M potassium phosphate, 0.2
mM EDTA pH 8.0, 50% glycerol).
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Primer name
MtTOP1-E24A forward
MtTOP1-E24A reverse
MtTOP1-E24Q forward
MtTOP1-E24Q reverse
MsTOP1-E21A forward
MsTOP1-E21A reverse
MsTOP1-E21Q forward
MsTOP1-E21Q reverse

Primer sequence (5’-3’)
CTTGGTGGGCGACGCGACGATGACCAG
CTGGTCATCGTCGCGTCGCCCACCAAG
CTTGGTGGGCGACTGGACGATGACCAGTC
GACTGGTCATCGTCCAGTCGCCCACCAAG
CCTTCGTCGGCGACGCGACAATCACGAGT
ACTCGTGATTGTCGCGTCGCCGACGAAGG
CTTCGTCGGCGACTGGACAATCACGAGTCG
CGACTCGTGATTGTCCAGTCGCCGACGAAG

Table 2.1 Primers used for site-directed mutagenesis.

Cleavage assay
The oligonucleotide substrate STS32 and MTS2-13 were labeled with γ32P-ATP at the 5’ end by T4 polynucleotide kinase (New England Biolabs)
(Table 2.2). The labeling reactions were carried on 37°C for 30 min and
terminated by heating at 75°C for 15 min.

32

P-labeled oligonucleotide substrates

were purified after the labeling reaction using a Sephadex G-50 (STS32) or
Sephadex G-25 spin column (MTS2-13). Purified substrates were eluted in 10
mM Tris-HCl, pH 8.0.

Serially diluted wild-type and mutant mycobacterial

topoisomerase I were incubated with 0.5 pmol STS32 or MTS2-13 in 5 µl of 10
mM Tris–HCl (pH 8.0) at 37°C for 30 min. To terminate the reactions, the equal
volume of cleavage stop buffer (79% formamide, 200 mM NaOH, 0.1mM EDTA,
0.04% bromophenol) was added to the reactions followed by heating at 95°C for
5 min.

The STS32 cleavage product was separated from the substrate by

electrophoresis in 15% sequencing gel. The MTS2-13 cleavage product was
separated from the substrate by electrophoresis in 20% sequencing gel. The
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TBE buffer was used as running buffer.

Gels were analyzed by Phosphor-

lmager.

Oligos name
STS32
MTS2-11
MTS2-13
MTS2-19
MTS2-18
MT7
MT6

Oligos sequence (5’-3’)
5′-CAGTGAGCGAGCTTCCGCêTTGACATCCCAATA-3′
5’-TTCCGCêTTGAC-3’
5’-TTCCGCêTTGACTT-3’
5’-CAGTGAGCGAGCTTCCGCT-3’
5’-CAGTGAGCGAGCTTCCGC-3’
5’-TTCCGCT-3’
5’-TTCCGC-3’

Table 2.2 Oligonucleotides used for mycobacterial activity assay. STS32, MTS11,
MTS2-13 were used as cleavage reaction substrates. MTS2-19, MTS2-18, MT7 ad MT6
were used as standards in electrophoresis analysis of the cleavage products.

Electrophoretic mobility shift assay (EMSA)
The oligonucleotide substrate STS32 was labeled with γ-32P-ATP at the
5’ end (Table 2.2). The electrophoretic mobility shift assay was carried on 10 µl
of 20 mM Tris-HCl (pH 8.0), 100 µg/ml BSA, 18% glycerol, 0.5 mM EDTA. 1-4
pmol of wild-type MtTOP1, MtTOP1-E24A and MtTOP1-E24Q were incubated
with 5 pmol STS32 at 37°C for 5 min. The reactions were placed on ice about 5
min. The non-covalent protein-DNA complex and free substrate were separated
with 8% polyacrylamide gel. 0.5×TBE buffer was used as running buffer. The
gels were vacuum dried at 80°C for 2 hr. The dried gel was analyzed by
Phosphor-lmager.
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Identification of cleavage site
The oligonucleotide substrate STS32, MTS2-11, MTS2-13, MTS2-19,
MTS2-18, MT7, and MT6 were labeled with γ-32P-ATP at the 5’ end (Table 2.2).
32

P-labeled oligonucleotide substrates MTS2-19 and MTS2-18 were purified after

the labeling reaction using Sephadex G-25 columns.

32

P-labeled oligonucleotide

substrates MT7 and MT6 were purified after the labeling reaction using
Sephadex G-15 columns (GE Healthcare). Purified substrates were eluted in 10
mM Tris-HCl, pH 8.0. 0.5 pmol STS32, MTS2-11 and MTS2-13 were incubated
with wild-type MtTOP1, wild-type MsTOP1, MtTOP1-704t and MsTOP1-701t in
10 mM Tris–HCl (pH 8.0) at 37°C for 15min.

Oligonucleotide MTS2-13 (0.5

pmol) was incubated with wild-type MtTOP1 in 10 mM Tris–HCl (pH 8.0) and
0.25 mM MgCl2 at 37°C for 15 min. The equal volume of cleavage stop buffer
was added to terminate reactions. The reactions were heated at 95 °C for 5 min.
MTS2-19, MTS2-18, MT7, and MT6 were used as standards in gel
electrophoresis to identify the cleavage site of mycobacterial topoisomerase I on
these oligonucleotide substrates. The cleavage product and standards were
electrophoresed in a sequencing gel (15% for substrate STS32, 20% gel for
MTS2-13 or other oligonucleotide substrates)
Religation assay
The oligonucleotide substrate MT3 and MTS2-13 were labeled with γ-32PATP at the 5’ end. Wild-type and mutant proteins (1 pmol) were incubated with
0.5 pmol oligonucleotide substrate in 5 µl 10 mM Tris-HCl (pH 8.0) at 37°C for 15
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min.

We added 0.25 mM or 2.5 mM MgCl2 into the cleavage reaction

respectively for 5 min further incubation at 37 °C. The reactions were terminated
with equal volume of loading buffer

(79% formamide, 0.2 M NaOH, 0.04%

bromophenol blue) and heated at 95°C for 5 min. The reaction products were
analyzed by electrophoresis in 15% sequencing gel. The TBE buffer was used
as running buffer. Gels were analyzed by Phosphor-lmager.

Relaxation assay
Wild-type and mutant mycobacterial topoisomerase I were serially diluted.
Diluted proteins were incubated with 250 ng negatively supercoiled plasmid
pBAD/thio (purified by CsCl density gradient centrifugation) in 20 µL of 10 mM
Tris–HCl (pH 8.0), 150 mM NaCl, 0.1 mg/ml gelatin, and 5 mM MgCl2 at 37°C for
30 min. The relaxation reactions were terminated by addition of 4 µL of stop
buffer (50 mM EDTA, 50% glycerol and 0.5% (v/v) bromophenol blue). The DNA
was then electrophoresed in a 1% agarose gel with TAE buffer (40 mM Trisacetate, pH 8.0, 2 mM EDTA). The gels were stained with 1 µg/mL ethidium
bromide for 1 hr and photographed over UV light.
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RESULTS
Cleavage and religation activity assay of MtTOP1-704t with oligonucleotide
MTS2-13
The MtTOP1-704t is used here for determination of the enzyme structure
by X-ray crystallography in collaboration with Dr. Kemin Tan at Argonne National
Laboratory.

The biochemical catalytic activity of MtTOP1-704t has been

described in Chapter 1. MtTOP1-704t lacks relaxation activity with negatively
supercoiled DNA.

It retains catenation and decatenation activity with single-

stranded circular or catenated kDNA.

It can cleave and religate long

oligonucleotides STS32, MT2, and short oligonucleotide MT3. In Figure 2.1, it
exhibits the cleavage activity with oligonucleotide MTS2-13. Wild-type MtTOP1
shows little cleavage activity with MTS2-13 because the oligonucleotide is
binding to the CTD under these reaction conditions. With the addition of Mg2+,
MtTOP1-704t religated cleaved MTS2-13 (Figure 2.2). These results indicates
that Mg2+ is required for catalysis but not for DNA cleavage.
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Figure 2.1 Assay of MTS2-13 cleavage by wild-type MtTOP1 and MtTOP1-704t. (A)
Assay of 32P-labeled MTS2-13 cleavage by wild-type MtTOP1 and MtTOP1-704t. (B)
Analysis of cleavage product from MT2-13 with wild-type MtTOP1 and MtTOP1-704t.
The average and standard deviation from two separate experiments is shown.

89

Figure 2.2 Religaton assay of MtTOP1-704t with MTS2-13. Wild-type MtTOP1-704t
reacted with 0.5 pmol MTS2-13 oligosubstrate 37 °C for 15 min. MgCl2 were added into
the cleavage reaction respectively for 5 min further incubation at 37 °C.
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The crystal structure of MtTOP1-704t
MtTOP1 contains four GxxGPY sequence motifs in its C-terminal region.
Based on the locations of the four GxxGPY repeats, we divided the region into
four repeat domains (Figure 1.1, Figure 1.2).

MtTOP1-704t is one of the

constructs that have been made based on the CTD prediction mentioned above.
It spans from amino acid A2 to amino acid T704 and includes the N-terminal
subdomains, D1-D4 along with C-terminal subdomain D5. The crystal structure
of MtTOP1-704t is showed in Figure 2.3 (PDB ID: 5D5H). The 15 N-terminal
residues (A2-S16) are not visible in the structure.

The NTD (G17-A638) of

MtTOP1-704t has a similar toroid assembly as EcTOP I (G2-N590) NTD (Tan et
al., 2016). The D1 subdomain contains the region from G17 to G50, and region
from P87 to D157. It is observed to have five β-turns and a short β-hairpin. The
hinge subdomain D2 comprises two sequentially separated regions: from F213 to
R302 (β1-β2-α1-β3) and from D434 to R516 (β4-β5-α2-β6). D3 is an all-α-helical
subdomain (from P303 to A433), including the catalytic residue Y342. The two
regions of D4 subdomain link to D1 and D5 subdomains.
The D5 subdomain is the first C-terminal subdomain of MtTOP1.

It

extends from residue R638 to P705. It contains a four-stranded antiparallel βsheet with a C-terminal helix packed against the β-sheet on one side (Figure
2.3). Hydrophobic interaction dominates the interaction between the β-sheet and
the helix. The helix apparently plays an important role in stabilizing the β-sheet
and the small subdomain. The conserved tyrosine Y665, the third residue of the
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β3 strand, is predicted to be a key residue in the interaction of D5 with DNA by
forming π-stackings with the bases.

B

A

D2
Y665
D5

D3

D1

D4

Figure 2.3 The crystal structure of MtTOP1-704t. (A) A ribbon diagram of the
structure of MtTOP1-704t. The N-terminal D1, D2, D3 and D4 subdomains, are colored
cyan, pink, blue and yellow. The C-terminal D5 subdomain is colored green. (B)
Structure of MtTOP1 first C-terminal subdomain D5. Conserved Y665 are highlighted.
The program Pymol was used for the preparation.
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Co-crystals of MtTOP1-704t with short ssDNA substrates
Co-crystallization trials of MtbTOPI-704t were set up with MTS
(Mycobacterial Topoisomerase Substrate) oligonucleotides of various lengths
with sequences derived from a 32 nucleotide long substrate (STS32) previously
identified as having a strong topoisomerase site (STS)(Bhat et al., 2009).
Multiple crystal forms were harvested, and their X-ray diffraction data were
collected. The highest resolution data set (2.42 Å) was obtained from a cocrystal with a short, 11-mer oligonucleotide (MTS2-11, 5’-TTCCGCTTGAC-3’).
This crystal structure (MtTOP1-704t/MTS2-11) (PDB: 6CQI) represents a
topoisomerase I/ssDNA complex in the absence of metal ions at the active site
(Figure 2.4).
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Figure 2.4 Structure of MtTOP1-704t/ssDNA complex. The ribbon diagram of one
structure of MtTOP1-704t in complex with MTS2-11. The five individual subdomains,
D1-D5 are colored in cyan, pink, blue, yellow and green, respectively. The phosphate
backbone of oligonucleotide is in orange with its polarity labeled. The catalytic residue,
Y342 is drawn for highlighting its position. The program Pymol was used for the
preparation.
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Conformation of ssDNA substrate and its kink
The ssDNA MTS2-11 is intact in the structure (Figure 2.4). Its sugarphosphate backbone is mostly buried along the bottom of the DNA-binding
groove from D4 to the edge of the D1-D3 interface in a 5’ to 3’ direction (Figure
2.4, Figure 2.5A).

The bases of the seven nucleotides from positions -4 to +3

resemble the stacking conformation of one B-DNA strand as described earlier for
DNA bound to E. coli topoisomerase III (EcTOP III) (Changela et al., 2001) and
topoisomerase I (EcTOP I)(Perry and Mondragón, 2003). This conformation is
interrupted between the -4 and -5 positions with a backbone kink and insertion of
a tyrosine side chain from the enzyme (Y176) between the two bases (Figure
2.5B).

The kink contributes to the recognition of cytosine at the -4 position

relative to the scissile phosphate for all preferred bacterial topoisomerase I
cleavage sites (Annamalai et al., 2009; Narula and Tse-Dinh, 2012; Zhang et al.,
2011). Aside from the interactions with the -4 cytosine base involving R168,
R172 and Y176, there are additional enzyme-ssDNA interactions, including a
series of arginine-phosphate salt bridges mediated by R194, R344 and R547
(Figure 2.5B and Figure 2.6).

95

Figure 2.5 Conformation of ssDNA substrate and its interaction to MtTOP1-704t.
(A) The ssDNA bound to MtTOP1-704t resembles a B-DNA conformation, which is
interrupted between -4 and -5 positions. The 2FoFc electron density map is drawn in
grey mesh and contoured at 1σ level and within 2.1 Å of the ssDNA, which is drawn in
stick format. (B) Part of interaction between ssDNA and MtTOP1-704t. Several arginine
residues involved in the interaction to either phosphate backbone (R194 and R547) or
bases (R167, R168 and R172) are presented. One anchoring site of ssDNA to MtTOP1704t is located at the phosphate group between -3 and -4 positions. The phosphate
group is positioned below the N-terminus of the α3 helix of D4, which has an equivalent
charge about +0.5 unit. In the apo structures of MtTOP1-704t, a phosphate group or a
sulfide group from crystallization buffer is commonly found at this position. The tyrosine
Y176 inserts between the bases at -4 and -5 positions, helping create a kink on the base
packing of ssDNA. The residue Y176 forms π-π stacking with bases at both -4 and -5
positions. Both Fig.2A and 2B were prepared based on the MtTOP1-704t/MTS2-11
structure (PDB code: 6CQI).
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Active-site conformation in the absence of Mg2+-binding
The conformational change upon ssDNA binding not only helps create the
gate for the passing of the T-strand, it also brings catalytic residues together to
form an active site. The active site configuration of MtTOP1-704t/ MTS2-11, in
the absence of Mg2+ ion, is similar to that of the covalent complex of EcTOP I
and EcTOP III/ssDNA complexes, but with new features (Figure 2.6A).

The

catalytic tyrosine Y342 makes two hydrogen bonds from top to the scissile
phosphate, including one to its bridging 5’-oxygen atom and one to a nonbridging O atom (Figure 2.6 A). The distance between the hydroxyl groups of
Y342 to the phosphorous of the scissile phosphate is 2.96 Å.

The scissile

phosphate is being positioned on one side by R344 through an argininephosphate salt bridge, and on the other side by E24 through a hydrogen bond
from its bridging 3’-oxygen atom (Figure 2.6A). E24 also forms a hydrogen bond
with the amide group of D111, bridging the catalytic residue to the scissile
phosphate.
The MtTOP1-704t/MTS2-11 structure does not have any positively
charged lysine side chain interacting with the DNA at the active site while in the
EcTOP III/ssDNA complex, lysine K8 interacts with the putative scissile
phosphate. The positively charged K8 was believed to help stabilize the negative
charge on non-bridging oxygens of the pentavalent transition state (Changela et
al., 2001). However, in MtTOP1 as well as in EcTOP I, this lysine residue is not
conserved, being replaced by a serine in the bacterial topoisomerase I
sequences (Strahs et al., 2006). A nearby lysine K28 in MtTOP1 (equivalent to
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K13 in EcTOP I) is more than 6.5 Å away from the scissile phosphate by
measuring the distances between K28 Nζ atom to the oxygen atoms of the
phosphate (Figure 2.6 A). The absence of EcTOP III K8 equivalent in MtTOP1
and EcTOP I active site structures implies some difference in the catalytic
mechanisms of bacterial topoisomerase I and topoisomerase III, as suggested
earlier (Terekhova et al., 2012; Zhang et al., 2011). The side chain of D111 is
quite mobile without well-defined electron density in electron density maps.
D111 can potentially make a hydrogen bond with an invariant H389 on the long
loop between α3 and α4 helices of D3. H389 also forms a displaced and tilted π
H (hydrogen) interaction with Y342 in this MtTOP1-704t/MTS2-11 complex. It is
noted that the α3_α4 loop of D3 is very flexible, allowing the position and
conformation of the strictly conserved histidine to be highly variable from
structure to structure. Similar observations were made for the covalent EcTOP I
complex as well as in the open and the mutant forms of EcTOP III, in which the
histidine forms a nearly parallel displaced π-π stacking with catalytic tyrosine.
However, in the closed and the intermediate forms of EcTOP III, there is no
interaction between these two residues. This flexible α3_ α4 loop of D3 and the
conserved histidine could play a potential role in charge relay in the DNA
cleavage and religation steps (Perry and Mondragon, 2002).

The direct π-π

interaction with the catalytic tyrosine may also allow this invariant histidine to
assist in stabilization of the transition state for DNA cleavage in the absence of
Mg2+.
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Structure of active site with bound Mg2+ ion
Magnesium plays an essential role in DNA religation by type IA
topoisomerase (Tse-Dinh, 1986).

However, divalent ion has never been

observed in any co-crystal structures of topoisomerase IA-DNA complex.

After

the extensive screening of MtTOP1-704t/ssDNA crystals grown under different
conditions, one crystal structure of MtTOP1-704t in complex with a 13-mer
oligonucleotide, MTS2-13 reveals a mode of metal binding at the enzyme active
site (Figure 2.6B).

Compared to the structure of MtTOP1-704t/ssDNA in the

absence of metal ion (Figure 2.6A), the extra electron densities in an
approximately globular shape between the scissile phosphate and the carboxyl
groups of E24 and D111 strongly indicate a metal binding site, Mg2+(1) in Figure
2.6B. One water molecule, W (1), was assigned to completes the coordination of
the metal ion, forming a trigonal bipyramid genometr, in which E24, OP1 and W1
are equatorial ligands while D111 and O3 are axial. It is worthwhile to mention
that the position of the sidechain of D111 is not well-defined in electron density
maps. After applying only Mg-O bond distance restrain (2.10 ± 0.10 Å) to the
metal binding site in the subsequent structural refinements, the trigional pyramid
geometry is quite stable and the model fits the electron densities well.
Interestingly, the water W1 forms a hydrogen bond with another TOPRIM acidic
residue D113 (Figure 2.6B) proposed previously (Aravind et al., 1998; Bhat et al.,
2009) to interact with divalent Mg2+. After obtaining this MtTOP1-704t/MTS213/Mg complex structure, a second structure with a metal ion bound at the same
site was determined after extensive screening of crystals formed in different
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conditions, particularly in conditions with added MgCl2 in the crystallization
buffers. The addition of Mg2+ in the crystallization buffer did not simply increase
Mg2+ binding, at least under the buffer condition used.

Figure 2.6 Active sites in the absence and in the presence of Mg2+. (A) The active
site interaction pattern between MtTOP1-704t and ssDNA (MTS2-11) in the absence of
Mg2+. The key residues from MtTOP1-704t and ssDNA are drawn in stick format. All
hydrogen bonds and salt bridges are drawn in magenta dash lines. The residue K28, as
discussed in text, is too far away from scissile phosphate. The 2FoFc electron density
map is drawn in grey mesh and contoured at 1s level and within 2.1 Å of the ssDNA, the
residues of E24, D111, D113 and Y342. (B) The active site interaction pattern between
MtTOP1-704t and ssDNA (MTS2-13) in the presence of Mg2+. The MtTOP1-704t
complex shown in this figure is slightly rotated along the horizontal axis in respect to that
shown in Figure 2.6A for better view of Mg2 binding site. Besides hydrogen bonds and
salt bridges, all Mg–O bonds are also drawn in magenta dash lines.
The 2FoFc
electron density map is drawn in grey mesh and contoured at 1σ level and within 2.1 Å
of the ssDNA, the residues of E24, D111, D113 and Y342, and the meal ion and water
molecules. The insert figure displays simulated annealing omit maps of metal-binding
site, 2Fo-Fc map in grey at contour level of 1σ, and Fo-Fc map in pink at contour level of
5σ. The simulated annealing refinement with a starting temperature of 5000K was
performed with Mg2+ and W1 being omitted.
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Mapping of exact cleavage site on single-stranded oligonucleotide
substrates
In each of the crystal structures of the enzyme-DNA complex reported
here, there is a DNA phosphate positioned at a distance from Tyr342 expected
for the scissile phosphate.

We confirmed that this is indeed the scissile

phosphate for the cleavage of oligonucleotides MTS2-11 and MTS2-13 by PAGE
analysis of the cleavage product, using shorter 5’-end labeled oligonucleotides
for comparison (Figure 2.7 A, B).

We also confirmed that both MtTOP1 and M.

smegmatis topoisomerase I (MsTOP1) cleave at the same site in oligonucleotide
STS32, a 32-base long ssDNA oligonucleotide from which the sequence of these
shorter oligonucleotide substrates has been derived (Figure 2.7C).

This

cleavage position is shifted by one nucleotide towards the 5’-end from the
position expected from the previous report (Bhat et al., 2009). This could be due
to differences in enzyme preparation, cleavage reaction conditions, and cleavage
site mapping protocols (Sikder and Nagaraja, 2000).
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Figure 2.7 Identification of cleavage site with MTS2-11, MTS2-13 and STS32
oligonucleotide substrate. (A) Identification of cleavage site with MTS2-11. Lane 1:
No enzyme. Lane 2: 1 pmol MtTOP1 cleavage product with oligo. Lane 3: 1 pmol
MtTOP1 cleavage product with 0.5 mM Mg2+ added. Lane4: 1 pmol MtTOP1 cleavage
product with 0.5 mM Mg2+ and 1 M NaCl added. Lane5: Oligo standard MT7. Lene6:
Oligo standard MT6. Lane 7: 1 pmol MtTOP1-704t cleavage product. Lane 8: 1 pmol
MtTOP1-704t cleavage product with 0.5mM Mg2+ added. Lane9: 1 pmol MtTOP1-704t
cleavage product with 0.5 mM Mg2+ and 1 M NaCl added. (B) Identification of cleavage
site with MTS2-13. Lane 4 and Lane 11: Oligo standard MT6. Lane 5 and Lane 12:
Oligo standard MT7. Lane 9 and lane 10 is cleavage product with 0.25mM Mg2+ added.
(C) Identification of cleavage site with STS32. 1 pmol MtTOP1-704t, MtTOP1 and
MsTOP1 were used in Lane 2,3 and 6. Lane 4: Oligo standard MTS2-18. Lane 5, Oligo
standard MTS2-19.
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Requirement of the strictly conserved Glu24 carboxyl side chain for DNA
cleavage
The ~100 amino acid long TOPRIM domains found in type IA and type IIA
topoisomerases have two strictly conserved sequence motifs of acidic residues
that play important roles in the catalysis of these topoisomerases, as well as
other nucleotidyl transfer enzymes that require Mg2+ for their activities (Aravind et
al., 1998).

The first motif is centered around a conserved glutamate that

corresponds to residue E24 in MtTOP1 and E9 in EcTOP I respectively. The
second motif is at the two conserved aspartates present as DxD (D111 and D113
in MtTOP1).

Site-directed mutagenesis of EcTOP I has shown that alanine

substitution at E9 abolishes DNA relaxation activity, and the E9A mutant could
not cleave DNA (1998; Zhu et al., 1998). A role for this conserved glutamate in
acid-base catalysis of DNA cleavage and rejoining has been proposed, with the
glutamate side chain providing the proton for the 3’-OH leaving group during
DNA cleavage, and enhancing the nucleophilic properties of the 3’-OH during
DNA religation. E24 of MtTOP1 is well positioned for these roles as seen in the
structure with MTS2-11 in the absence of divalent ions as the likely structure
prior to the DNA cleavage step, and in the structure with MTS2-13 in the
presence of Mg2+ as the probable structure post DNA religation. The critical
functions of the strictly conserved glutamate E24 may be assisted by charge
relay involving D111 and H389, with water molecules in the hydrogen-bonding
network at the active site being potential participants in the acid-base catalysis.
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D111 and H365 in EcTOP I are well positioned for the proposed charge relay
(Perry and Mondragon, 2002).

The sequence of charge relay during DNA

cleavage would involve donation of a proton from the invariant histidine to the
nearby aspartate, which then relays the charge to the strictly conserved
glutamate so that it can be protonated at physiological pH to act as a general
acid for neutralizing the negative charge on the 3’-hydroxyl leaving group. The
bell-shaped pH dependence of EcTOP I catalysis is modified by H365 mutations
(Perry and Mondragon, 2002) is consistent with the role of this conserved
histidine in optimal catalysis at physiological pH (Perry and Mondragon, 2002). A
nearby water molecule can potentially replace the role of the histidine for
donating a proton if the histidine is mutated to another residue. However, the
role of EcTOP I glutamate E9 as a general acid during DNA cleavage is
inconsistent with the reported retention of DNA cleavage activity for the EcTOP I
E9Q mutant (Chen and Wang, 1998). In order to clarify the catalytic role of this
critical conserved glutamic acid residue, we mutated E24 of MtTOP1 to alanine
or glutamine.

Both the MtTOP1-E24A and MtTOP1-E24Q mutants had null

relaxation activity as well as no observable DNA cleavage activity (Figure 2.8 A,
B). Similar results were obtained for the MsTOP1 E21A and E21Q mutants
(Figure 2.9).

Gel shift assay of non-covalent binding to the oligonucleotide

substrate showed that the activities of the MtTOP1-E24A and MtTOP1-E24Q
mutant proteins are unaffected prior to the DNA cleavage step (Figure 2.8C).
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Figure 2.8 Substitutions in MtTOP1 E24 prevent relaxation of supercoiled DNA and
ssDNA cleavage by the enzyme without affecting non-covalent DNA binding. (A)
Relaxation assay:
Agarose gel electrophoresis of products from incubation of
supercoiled pBAD/Thio plasmid DNA with wild-type MtTOP1 and E24A, E24Q mutant
enzymes at 37°C for 30 min. (B) ssDNA cleavage assay: STS32 oligonucleotide labeled
with 32P at the 5’-end was incubated with enzymes at 37°C for 15 min. The substrate
and product were separated by electrophoresis in a 15% sequencing gel. (C) ssDNA
binding assay of wild-type and mutant MtTOP1: Electrophoretic mobility shift assay for
formation of non-covalent complex between labeled STS32 oligonucleotide and
enzyme. The graph shows average and means from results of three experiments.
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Figure 2.9 Substitutions in MsTOP1-E21 prevent ssDNA cleavage by the enzyme.
(A) Relaxation assay. Serial diluted MsTOP1, MsTOP1-E21A and MsTOP1-E21Q were
incubated with 250 ng pBAD/Thio plasmid DNA 37°C for 30min. (B) ssDNA cleavage
assay. ssDNA cleavage assay: STS32 oligonucleotide labeled with 32P at the 5’-end
was incubated with enzymes at 37°C for 15 min. The substrate and product were
separated by electrophoresis in a 15% sequencing gel.
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DISSCUSSION
In the model of DNA cleavage proposed for type IIA topoisomerases
(Schmidt et al., 2010), a divalent metal ion and a conserved arginine interact with
the scissile phosphate to stabilize the transition state while a second metal ion
interacts with the -1 phosphate to position the scissile phosphate in the active
site for cleavage by the tyrosine nucleophile.

We propose that for bacterial

topoisomerase I, the strictly conserved arginine (R344 in MtTOP1) is mainly
responsible for an electrostatic interaction with the scissile phosphate to allow
DNA cleavage to take place in the absence of metals (Figure 2.10A).

A water

molecule may act as a general base (B:) to extract a proton from the active site
tyrosine Y342, facilitating nucleophilic attack. The positively charged side chain
of R344 interacts with both the tyrosine oxygen and the transition state to
stabilize the negative charges. E24 acts as general acid to protonate the 3’-O
leaving group. D111 and H389 are in place for charge relay to assist E24. This
proposed scheme is supported by the previously observed requirement of Mg2+
for DNA cleavage by EcTOP I mutants with the conserved arginine (R321)
altered to an aromatic residue that can interact with the active site tyrosine
through hydrophobic interaction, but cannot provide any electrostatic interaction
(Narula et al., 2011; Narula and Tse-Dinh, 2012).

The stacking interaction

between the invariant histidine (H389 in MtTOP1) and the catalytic tyrosine may
also help to stabilize the DNA cleavage transition state in the absence of Mg2+.
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A

B

Figure 2.10 Proposed schemes for DNA cleavage and religation. (A) Proposed
schemes for DNA cleavage in the absence of divalent ions. (B) Proposed schemes for
DNA reliagtion in the presence of divalent ion.

The preferred DNA cleavage sites of MtTOP1 have a cytosine base at the
-4 position upstream of the scissile phosphate (Annamalai et al., 2009). This
cleavage site preference holds true for all bacterial topoisomerase I, but not for
topoisomerase III. We propose that the interactions of R168, R172, Y176 (Figure
2.5) with the cytosine base in the -4 position serve the role of the second metal
ion proposed for type IIA topoisomerase for positioning the DNA substrate
(Schmidt et al., 2010), ensuring that the tyrosine hydroxyl is at the required
distance from the scissile phosphate in the active site for DNA cleavage to take
place. Analysis of the site-directed alanine substitution mutations of the EcTOP I
residues required for interaction with the cytosine in the -4 position showed that
the mutants have significantly decreased DNA cleavage activity, and that the
preference of the cytosine in the -4 position can be altered to an adenine base
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instead (Narula and Tse-Dinh, 2012). Topoisomerase III enzymes do not have
the requirement of a cytosine base in the -4 position for preferred cleavage sites
to utilize this mechanism for aligning the active site tyrosine with the scissile
phosphate. A lysine conserved in topoisomerase III enzymes (K8 in EcTOP III)
has been proposed to replace the role of a metal ion required by type IIA
topoisomerase in the active site (Schmidt et al., 2010). A lysine is conserved in
bacterial topoisomerase I in a nearby, but non-equivalent position (K13 in EcTOP
I, K28 in MtTOP1). Site-directed mutagenesis of EcTOP I K13 showed that this
lysine is required for DNA cleavage (Strahs et al., 2006), but its positively
charged side chain is not in the vicinity of the scissile phosphate in all the EcTOP
I crystal structures available to date. We also find that K28 is not near the DNA
phosphates in the active site of MtTOP1-704t bound to DNA in the absence or
presence of metal ions (Figure 2.6). We cannot dismiss the possibility that K28
of MtTOP1 and its equivalent lysine in other bacterial topoisomerase I can move
into the active site to interact with the transition state in a reaction intermediate
that has not been captured by crystallography. It is also possible that the role of
K13 in EcTOP I and K28 in MtTOP1 in catalysis is different from K8 in EcTOP III,
as their positions are not equivalent.

The lysine conserved in this specific

position of bacterial topoisomerase I may be required for the assembly of the
active site. It may also have a polarizing effect on the nearby acidic residues, as
previously proposed (Strahs et al., 2006).
Because type IA topoisomerases break and rejoin a single-strand of DNA that
is not base-paired to its complementary strand, Watson-Crick base pairing is not
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available to help align the 3’-OH and 5’-phosohoryl group linked to the tyrosine in
the covalent intermediate for rejoining. Therefore, we propose that there is a
stringent requirement for the presence of the metal ion to be present for these
DNA ends to be joined into a phosphodiester linkage in the DNA religation step.
Metal ion is required to position the 3’-hydroxyl group as the nucleophile at a
required distance from the phosphotyrosine linkage. The metal ion could be
involved in positioning the 5’-phosphoryl tyrosine, and in the stabilization of the
transition state for DNA rejoining (Figure 2.10B). Such roles for the divalent ion
would differ from the classic two-metal ion mechanism, with both metal ions
interacting with the transition state, and one metal assisting in the activation of
the nucleophile while the other metal stabilizes the leaving group (Strahs et al.,
2006). There are also significant differences from the mechanism proposed for
type IIA topoisomerase (Schmidt et al., 2010), with both metal ions assisting the
acid-base catalysis by interacting with the transition state and the second metal
ion interacting with an adjacent phosphate to anchor the substrate DNA. We
cannot disregard any movement of the metal ion in type IA and type IIA
topoisomerases during catalysis to facilitate nucleophile formation and stabilize
both transition state and leaving group as expected for the canonical two-metal
ion mechanism (Schmidt et al., 2010; Strahs et al., 2006).

Nevertheless,

bacterial topoisomerase I may have evolved to have a metal ion involved in
forming and stabilizing the transition state for DNA rejoining because of the
single-stranded state of the DNA strand during cleavage-religation, and the
utilization of a cytosine binding pocket for positioning the DNA substrate for
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cleavage instead of using a metal ion for such purpose. The 3’-OH nucleophile is
activated by Mg2+ in DNA rejoining (Figure 2.10B). The positive charge of the
conserved arginine (R344 in MtTOP1) interacting with the active site tyrosineleaving group is essential for DNA rejoining.

DNA cleavage intermediate

accumulates in vivo when this arginine in EcTOP I (R321) is mutated to a
hydrophobic amino acid (Narula et al., 2011). The presence of Mg2+ cannot
compensate for the absence of the arginine positive charge for DNA rejoining.
Therefore even though a metal may be in a position to stabilize the negative
charge of the tyrosine hydroxyl leaving group as expected for the canonical twometal ion mechanism, the positive charge of this arginine is still required for
interacting with the tyrosine hydroxyl negative charge during DNA rejoining.
Certain mutants of EcTOP I and MsTOP1 with specific substitutions at the
conserved arginine and aspartates in the active site have been demonstrated to
be dominant lethal (Bhat et al., 2009; Tse-Dinh, 2009). These mutant enzymes
can still cleave DNA while DNA rejoining in the presence of Mg2+ became less
efficient, resulting in accumulation of covalent intermediates and bacterial cell
death (Cheng et al., 2009; Narula et al., 2011; Tse-Dinh, 2009). MtTOP1 is
essential for the viability of the TB pathogen, and can be exploited as a novel
target for discovery of new therapies (Godbole et al., 2015; Nagaraja et al., 2017;
Ravishankar et al., 2015; Sandhaus et al., 2016) in the treatment of MDR-TB.
Genetic manipulation to deplete MtTOP1 and inhibition of MtTOP1 activity by
small molecules have been shown to inhibit growth (Godbole et al., 2015;
Ravishankar et al., 2015). Significant bactericidal activity may require only a
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small number of the trapped covalent topoisomerase-DNA intermediates (Aedo
and Tse-Dinh, 2012) through the action of topoisomerase poison inhibitors
(Pommier, 2013; Pommier et al., 2010). Small molecules that can selectively
perturb the MtTOP1 active site interactions in the presence of Mg2+ observed in
the structure of enzyme/DNA/Mg complex reported here may be candidates for
topoisomerase poison inhibitors against MtTOP1.
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